

Supplementary Information

Stereodivergent Synthesis of Enantioenriched Azepino[3,4,5-*cd*]-Indoles via Cooperative Cu/Ir-Catalyzed Asymmetric Allylic Alkylation and Intramolecular Friedel-Crafts Reaction

Lu Xiao,^{1,2,4} Bo Li,^{3,4} Fan Xiao,¹ Cong Fu,¹ Liang Wei,¹ Yanfeng Dang,^{3,*} Xiu-Qin Dong,^{1,*} Chun-Jiang Wang^{1,2*}

¹College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China; ²State Key Laboratory of Elemento-organic Chemistry, Nankai University, Tianjin 300071, China; ³Tianjin Key Laboratory of Molecular Optoelectronic Sciences, Department of Chemistry, Tianjin University, Tianjin 300072, China; ⁴These two authors contributed equally

E-mail: yanfeng.dang@tju.edu.cn (Y.D.); xiuqindong@whu.edu.cn (X.-Q.D.); cjwtang@whu.edu.cn (C.-J.W.)

Table of Contents




1. General Remarks.....	S2
2. Preparation and characterization data of 4-indolyl allyl carbonates.....	S2
3. General Procedures and Characterization for Azepino[3,4,5- <i>cd</i>]-Indoles.....	S8
4. Scale-Up Experiments and Synthetic Transformation.....	S40
5. TFA-Promoted C9-Epimerization of 6,9- <i>cis</i> - 3a	S44
6. One-pot allylation/cyclization/epimerization with TFA as the cyclization promoter.....	S48
7. References.....	S49
8. X-ray Structures of (6 <i>S</i> ,7 <i>S</i> ,9 <i>R</i>)- 3a , (6 <i>R</i> ,7 <i>R</i> ,9 <i>R</i>)- 3a , and (6 <i>R</i> ,7 <i>S</i> ,9 <i>R</i>)- 3a	S50
9. NMR and HPLC Spectra.....	S52

1. General Remarks


¹H NMR spectra were recorded on a Bruker Mercury 400 MHz spectrometer in CDCl₃. Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data were reported as (s = single, d = double, t = triple, q = quartet, m = multiple or unresolved, and brs = broad single). ¹³C NMR spectra were recorded on a Bruker 100 MHz spectrometer in CDCl₃. Chemical shifts were reported in ppm with the internal chloroform signal at 77.0 ppm as a standard. ¹⁹F NMR spectra were recorded on a Bruker 376 MHz spectrometer in CDCl₃. Chemical shifts were reported in ppm with the internal CF₃COOH signal at -76.55 ppm. The data were reported as (s = single, d = double, t = triple, q = quarter, m = multiple or unresolved, br s = broad single, coupling constant (s) in Hz, integration). Commercially available reagents were used without further purification. Solvents were purified prior to use according to the standard methods. Unless otherwise stated, all reactions were set up under nitrogen atmosphere in oven-dried glassware using standard Schlenk techniques, monitored by TLC with silica-gel coated plates and purified by flash column chromatography. The enantiomeric excesses (ee) of the products were determined by high-performance liquid chromatography (HPLC) analysis performed on Agilent 1200 Series chromatographs using a Diacel chiral column (25 cm). Optical rotations were measured on an Rudolph Research Analytical Autopol VI polarimeter with [α]³⁰D values reported in degrees; concentration (c) is in 0.5 g/100 mL. Aldimine esters,¹ 4-indolyl allylic carbonates² chiral ligands **L1-L3**³, **L4**⁴, **L5**⁵ and **L6**⁶ were prepared according to the literature procedure. The racemic products were obtained by blending equal amount of two enantiomers. The absolute configuration of the products (*6S,7S,9R*)-**3a**, (*6R,7R,9R*)-**3a**, and (*6R,7S,9R*)-**3a** were assigned by X-ray diffraction analysis.

2. Preparation and characterization data of 4-indolyl allyl carbonates 2

In general, 4-indolyl allyl carbonates **2** were prepared according to the procedure as shown below.²




(E)-methyl (3-(1-methyl-1*H*-indol-4-yl)allyl) carbonate (2a): Yield (88% yield, overall 3 steps); white solid; m.p. 66–68 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.28 – 7.15 (m, 3H), 7.12 – 7.01 (m, 2H), 6.68 – 6.64 (m, 1H), 6.52 – 6.42 (m, 1H), 4.86 (dd, *J* = 6.4, 1.2 Hz, 2H), 3.80 (s, 3H), 3.77 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 155.7, 137.0, 133.7, 129.2, 128.3, 126.7, 122.8, 121.5, 117.7, 109.2, 99.3, 69.0, 54.7, 32.9. HRMS (ESI+) Calcd. For C₁₄H₁₆NO₃⁺ ([M+H]⁺): 246.1125, found: 246.1123. IR (thin film) ν (cm⁻¹) 3054, 2986, 2305, 1748, 1442, 1265, 969, 739.



(Z)-methyl (3-(1-methyl-1*H*-indol-4-yl)allyl) carbonate⁷ (2a'): Yield (93% yield, from the corresponding allyl alcohol); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.29 – 7.25 (m, 1H), 7.23 – 7.17 (m, 1H), 7.06 (d, *J* = 3.2 Hz, 1H), 7.03 (s, 1H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.47 (dd, *J* = 3.2, 0.4 Hz, 1H), 5.95 (dt, *J* = 11.6, 6.4 Hz, 1H), 4.92 (dd, *J* = 6.4, 1.6 Hz, 2H), 3.78 (s, 3H), 3.77 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 155.7, 136.6, 131.6, 128.9, 128.1, 127.5, 125.1, 121.3, 119.5, 108.9, 99.5, 65.4, 54.7, 32.9. IR (thin film) *v* (cm⁻¹) 3054, 2986, 2304, 1748, 1421, 1265, 896, 740.




(E)-3-(5-fluoro-1-methyl-1*H*-indol-4-yl)allyl methyl carbonate (2x): Yield (86% yield, overall 3 steps); white solid; m.p. 58-60 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.18 – 7.13 (m 1H), 7.12 (d, *J* = 3.2 Hz, 1H), 7.10 – 7.02 (m, 1H), 6.96 (dd, *J* = 11.2, 8.8 Hz, 1H), 6.66 (dd, *J* = 3.2, 0.8 Hz, 1H), 6.64 – 6.57 (m, 1H), 4.88 (dd, *J* = 6.4, 1.2 Hz, 2H), 3.82 (s, 3H), 3.78 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 155.9 (d, *J* = 235.6 Hz), 155.7, 133.4, 130.6, 126.97 (dd, *J* = 21.2, 4.0 Hz), 126.29 (d, *J* = 7.2 Hz), 114.22 (d, *J* = 13.6 Hz), 110.3, 110.0, 109.63 (d, *J* = 10.6 Hz), 100.11 (d, *J* = 5.2 Hz), 69.3, 54.8, 33.1. ¹⁹F NMR (376 MHz, CDCl₃) δ -127.2. HRMS (ESI+) Calcd. For C₁₄H₁₄FNNaO₃⁺ ([M+Na]⁺): 286.0850, found: 386.0847. IR (thin film) *v* (cm⁻¹) 3054, 2986, 2305, 1750, 1442, 1265, 869, 740.




(E)-3-(6-fluoro-1-methyl-1*H*-indol-4-yl)allyl methyl carbonate (2y): Yield (89% yield, overall 3 steps); yellow liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.29 – 7.27 (m, 1H), 7.05 (dd, *J* = 8.8, 1.6 Hz, 1H), 7.02 – 6.98 (m, 1H), 6.99 – 6.95 (m, 1H), 6.50 – 6.47 (m, 1H), 6.47 – 6.39 (m, 1H), 4.86 (dd, *J* = 6.4, 1.2 Hz, 2H), 4.06 (s, 3H), 3.82 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 160.04 (d, *J* = 239.0 Hz), 155.6, 132.07 (d, *J* = 12.8 Hz), 131.25 (d, *J* = 2.4 Hz), 129.86 (d, *J* = 9.6 Hz), 124.9, 123.51 (d, *J* =


3.6 Hz), 119.0, 106.24 (d, J = 25.2 Hz), 96.6, 94.53 (d, J = 27.6 Hz), 68.4, 65.9, 54.9. ^{19}F NMR (376 MHz, CDCl_3) δ -119.9. IR (thin film) ν (cm^{-1}) 3054, 2986, 2305, 1749, 1442, 1265, 949, 740.




(E)-3-(7-fluoro-1-methyl-1*H*-indol-4-yl)allyl methyl carbonate (2z): Yield (87% yield, overall 3 steps); white solid; m.p. 64–66 °C, ^1H NMR (400 MHz, CDCl_3) δ 7.16 – 6.94 (m, 3H), 6.86 – 6.78 (m, 1H), 6.70 – 6.65 (m, 1H), 6.44 – 6.23 (m, 1H), 4.90 – 4.80 (m, 2H), 3.99 (s, 3H), 3.81 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 150.35 (d, J = 245.6 Hz), 132.9, 130.8, 130.70 (d, J = 5.6 Hz), 124.60 (d, J = 14.0 Hz), 122.2, 118.11 (d, J = 6.8 Hz), 107.24 (d, J = 18.6 Hz), 107.24 (d, J = 18.6 Hz), 100.3, 69.0, 54.8, 35.7. ^{19}F NMR (376 MHz, CDCl_3) δ -136.6. HRMS (ESI+) Calcd. For $\text{C}_{14}\text{H}_{14}\text{FNNaO}_3^+$ ([M+Na] $^+$): 286.0850, found: 386.0847. IR (thin film) ν (cm^{-1}) 3054, 2986, 2305, 1748, 1442, 1265, 896, 739.




(E)-3-(6-bromo-1-methyl-1*H*-indol-4-yl)allyl methyl carbonate (2A): Yield (89% yield, overall 3 steps); white solid; m.p. 60–62 °C, ^1H NMR (400 MHz, CDCl_3) δ 7.42 – 7.38 (m, 1H), 7.35 – 7.32 (m, 1H), 7.06 (d, J = 3.2 Hz, 1H), 6.98 (d, J = 16.0 Hz, 1H), 6.61 (dd, J = 3.2, 0.8 Hz, 1H), 6.50 – 6.40 (m, 1H), 4.86 (dd, J = 6.4, 1.2 Hz, 2H), 3.82 (s, 3H), 3.76 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 137.8, 131.9, 129.8, 127.8, 125.7, 124.4, 120.4, 115.2, 112.0, 99.7, 68.6, 54.8, 33.1. HRMS (ESI+) Calcd. For $\text{C}_{14}\text{H}_{14}^{78.9183}\text{BrNO}_3^+$ ([M+H] $^+$): 346.0049, found: 346.0047; $\text{C}_{14}\text{H}_{14}^{80.9163}\text{BrNO}_3^+$ ([M+H] $^+$): 348.0029, found: 348.0030. IR (thin film) ν (cm^{-1}) 3054, 2986, 2305, 1750, 1442, 1264, 896, 744.




(E)-methyl (3-(1-methyl-6-phenyl-1*H*-indol-4-yl)allyl) carbonate (2B): Yield (85% yield, overall 3 steps); white solid; m.p. 80–82 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.72 – 7.64 (m, 2H), 7.49 – 7.41 (m, 4H), 7.36 – 7.30 (m, 1H), 7.16 – 7.08 (m, 2H), 6.67 (d, *J* = 3.2 Hz, 1H), 6.58 – 7.48 (m, 1H), 4.89 (dd, *J* = 6.4, 1.2 Hz, 2H), 3.83 (s, 3H), 3.82 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 155.7, 142.2, 137.6, 135.3, 133.6, 129.9, 128.7, 128.5, 127.4, 126.7, 126.0, 123.3, 117.8, 107.8, 99.4, 69.0, 54.8, 33.0. HRMS (ESI+) Calcd. For C₂₀H₁₉NNaO₃⁺ ([M+Na]⁺): 344.1257, found: 344.1254. IR (thin film) ν (cm⁻¹) 3054, 2986, 2305, 1748, 1442, 1265, 895, 739.




(E)-methyl (3-(1-methyl-6-vinyl-1*H*-indol-4-yl)allyl) carbonate (2C): Yield (86% yield, overall 3 steps); yellow liquid, ¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.26 (m, 2H), 7.08 (d, *J* = 3.2 Hz, 1H), 7.05 (d, *J* = 16.0 Hz, 1H), 6.83 (dd, *J* = 17.6, 10.8 Hz, 1H), 6.62 (dd, *J* = 3.2, 0.8 Hz, 1H), 6.52 – 6.44 (m, 1H), 5.77 (dd, *J* = 17.6, 0.8 Hz, 1H), 5.25 – 5.14 (m, 1H), 4.87 (dd, *J* = 6.4, 1.2 Hz, 2H), 3.81 (s, 3H), 3.79 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 155.7, 137.6, 137.3, 133.5, 131.5, 130.0, 128.3, 126.6, 123.2, 116.3, 112.0, 107.3, 99.6, 68.9, 54.8, 32.9. HRMS (ESI+) Calcd. For C₁₆H₁₇NNaO₃⁺ ([M+H]⁺): 294.1101, found: 294.1097. IR (thin film) ν (cm⁻¹) 3054, 2986, 2305, 1748, 1442, 1265, 896, 739.



(E)-3-(6-cyclopropyl-1-methyl-1*H*-indol-4-yl)allyl methyl carbonate (2D): Yield (88% yield, overall 3 steps); yellow liquid, ^1H NMR (400 MHz, CDCl_3) δ 7.10 – 6.94 (m, 4H), 6.58 (d, J = 3.2 Hz, 1H), 6.50 – 6.40 (m, 1H), 4.85 (dd, J = 6.4, 1.2 Hz, 2H), 3.81 (s, 3H), 3.74 (s, 3H), 2.07 – 1.97 (m, 1H), 1.02 – 0.90 (m, 2H), 0.78 – 0.67 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 137.5, 137.4, 133.8, 128.8, 128.0, 124.9, 122.8, 116.7, 106.4, 99.2, 69.1, 54.8, 32.9, 29.7, 15.8, 8.8. HRMS (ESI+) Calcd. For $\text{C}_{17}\text{H}_{19}\text{NNaO}_3^+$ ($[\text{M}+\text{Na}]^+$): 308.1257, found: 308.1254. IR (thin film) ν (cm^{-1}) 3054, 2986, 2305, 1748, 1422, 1265, 896, 740.




(E)-3-(1-allyl-1*H*-indol-4-yl)allyl methyl carbonate (2E): Yield (84% yield, overall 3 steps); yellow liquid; ^1H NMR (400 MHz, CDCl_3) δ 7.28 – 7.20 (m, 2H), 7.20 – 7.16 (m, 1H), 7.15 – 7.12 (m, 1H), 7.08 (d, J = 16.0 Hz, 1H), 6.70 (d, J = 3.2 Hz, 1H), 6.52 – 6.40 (m, 1H), 6.05 – 5.84 (m, 1H), 5.19 (dd, J = 10.4, 1.2 Hz, 1H), 5.11 – 5.01 (m, 1H), 4.87 (dd, J = 6.6, 1.2 Hz, 2H), 4.74 – 4.70 (m, 2H), 3.81 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 136.4, 133.6, 133.3, 128.4, 128.3, 126.9, 122.9, 121.6, 117.8, 117.3, 109.6, 99.8, 69.0, 54.8, 48.9. HRMS (ESI+) Calcd. For $\text{C}_{16}\text{H}_{18}\text{NO}_3^+$ ($[\text{M}+\text{H}]^+$): 272.1281, found: 264.0788. HRMS (ESI+) Calcd. For $\text{C}_{16}\text{H}_{17}\text{NNaO}_3^+$ ($[\text{M}+\text{Na}]^+$): 294.1101, found: 294.1098. IR (thin film) ν (cm^{-1}) 3054, 2986, 2306, 1747, 1442, 1265, 941, 740.




(E)-3-(1-benzyl-1*H*-indol-4-yl)allyl methyl carbonate (2F): Yield (86% yield, overall 3 steps); white solid; m.p. 78–80 °C, ^1H NMR (400 MHz, CDCl_3) δ 7.31 – 7.26 (m, 3H), 7.25 – 7.20 (m, 2H),

7.18 (d, $J = 3.2$ Hz, 1H), 7.16 – 7.05 (m, 4H), 6.74 (d, $J = 3.2$ Hz, 1H), 6.50 – 6.44 (m, 1H), 5.33 (s, 2H), 4.87 (dd, $J = 6.4, 1.2$ Hz, 2H), 3.81 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.8, 137.4, 136.7, 133.6, 128.8, 128.5, 127.7, 127.0, 126.7, 123.0, 121.8, 118.0, 109.8, 100.1, 69.1, 54.8, 50.2. HRMS (ESI $^+$) Calcd. For $\text{C}_{20}\text{H}_{19}\text{NNaO}_3^+ ([\text{M}+\text{Na}]^+)$: 344.1257, found: 344.1255. IR (thin film) ν (cm^{-1}) 3054, 2986, 2305, 1748, 1422, 1265, 896, 740.



(E)-3-(1H-indol-4-yl)allyl methyl carbonate (2G): Yield (80% yield, overall 3 steps); yellow liquid; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (s, 1H), 7.33 (d, $J = 8.0$ Hz, 1H), 7.26 – 7.22 (m, 2H), 7.20–7.14 (m, 1H), 7.09 (d, $J = 16.0$ Hz, 1H), 6.75 – 6.72 (m, 1H), 6.55 – 6.40 (m, 1H), 4.87 (dd, $J = 6.4, 1.2$ Hz, 2H), 3.81 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 136.1, 133.7, 128.3, 126.1, 124.6, 122.9, 122.0, 118.1, 111.0, 101.0, 69.0, 54.8. HRMS (ESI $^+$) Calcd. For $\text{C}_{13}\text{H}_{13}\text{NNaO}_3^+ ([\text{M}+\text{Na}]^+)$: 254.0788, found: 254.0787. IR (thin film) ν (cm^{-1}) 3365, 3054, 2986, 2305, 1747, 1422, 1265, 896, 739.

3. General Procedures and Characterization for Azepino[3,4,5-*cd*]-Indoles




A flame dried Schlenk tube **A** was cooled to room temperature and filled with N_2 . To this flask were added $[\text{Ir}(\text{COD})\text{Cl}]_2$ (0.005 mmol), $(S,S,S)\text{-L5}$ (0.010 mmol), degassed THF (0.5 mL) and

degassed *n*-propylamine (0.5 mL). The reaction mixture was heated at 50 °C for 30 min and then the volatile solvents were removed under vacuum to gain a pale-yellow solid. Meanwhile, Cu(MeCN)₄BF₄ (0.01 mmol) and (*S,S_p*)-*i*Pr-Phosferrox-**L1** (0.011 mmol) were dissolved in 1.0 mL of DCE in a Schlenk tube **B**, and stirred at room temperature for about 40 min. Then, aldimine ester **1** (0.30 mmol), 4-indolyl allylic carbonate **2** (0.20 mmol) and K₂CO₃ (0.40 mmol) were added into the Schlenk tube **A** and filled with N₂. The Cu/**L1** complex solution was then transferred from the Schlenk tube **B** to the Schlenk tube **A** *via* syringe. Finally, the reaction mixture was continuously stirred at room temperature under N₂ atmosphere. Once starting material was consumed (monitored by TLC), the residue was separated by flash column chromatography to give the crude product. The crude product was dissolved in dichloromethane and two equivalent of the corresponding aldehyde and Zn(OTf)₂ (50 mol%) were added. Once starting material was consumed (monitored by TLC), the reaction was quenched with 1 mol of HCl solution (1 mL). The layers were separated, and the aqueous layer was extracted with DCM (5 mL x 3). The combined organic components were washed with saturated brine (10 mL), dried over anhydrous Na₂SO₄, filtration and evaporated in vacuum. After evaporation of the solvent under vacuum, the crude mixture was flushed with short silica gel plug to remove the metal complex and the diastereoselectivity was determined with ¹H NMR analysis. Then, the whole residue was further purified by column chromatography to give the desired product, which was then directly analyzed by HPLC to determine the enantiomeric excess.

Characterization for Azepino[3,4,5-*cd*]-Indoles:


Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3a)



Yield (67%); 18:1 dr; white solid; m.p. 198–200 °C; [α]³⁰_D = 63.0 (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 7.19 – 7.12 (m, 1H), 7.12 – 7.06 (m,


1H), 6.98 – 6.92 (m, 1H), 6.41 – 6.30 (m, 1H), 6.16 (s, 1H), 5.79 (s, 1H), 5.19 (dd, J = 17.2, 2.0 Hz, 1H), 5.10 (dd, J = 10.0, 2.0 Hz, 1H), 4.35 (d, J = 9.6 Hz, 1H), 3.59 (s, 3H), 3.58 (s, 3H), 1.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.4, 144.1, 138.2, 136.9, 134.8, 132.9, 129.5, 128.5, 125.9, 124.9, 122.0, 120.0, 118.9, 116.5, 107.2, 64.9, 56.7, 56.4, 51.7, 32.6, 26.5. HRMS (ESI+) Calcd. For $\text{C}_{23}\text{H}_{24}^{34.9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 395.1521, found: 395.1518; $\text{C}_{23}\text{H}_{24}^{36.9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 397.1491, found: 397.1498. IR (thin film) ν (cm^{-1}) 3334, 3047, 2929, 1727, 1576, 1486, 1135, 1089, 745. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.66 and 6.18 min.

Methyl (*6R,7R,9S*)-9-(4-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((*6R,7R,9S*)-3a)




Yield (62%); 17:1 dr; white solid; m.p. 198–200 °C; $[\alpha]^{30}_D$ = -61.4 (c 0.50, CH_2Cl_2); HRMS (ESI+) Calcd. For $\text{C}_{23}\text{H}_{24}^{34.9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 395.1521, found: 395.1521; $\text{C}_{23}\text{H}_{24}^{36.9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 397.1491, found: 397.1497. IR (thin film) ν (cm^{-1}) 3329, 3053, 2945, 1734, 1606, 1487, 1241, 1109, 746. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.66 and 6.18 min.

Methyl (*6R,7S,9S*)-9-(4-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((*6R,7S,9S*)-3a)




Yield (63%); 20:1 dr; white solid; m.p. 68-70 °C; $[\alpha]^{30}_D = -110.8$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, *J* = 8.4 Hz, 2H), 7.32 (d, *J* = 8.4 Hz, 2H), 7.21 – 7.10 (m, 2H), 6.99 – 6.95 (m, 1H), 6.34 (ddd, *J* = 17.2, 10.4, 8.8 Hz, 1H), 6.23 (s, 1H), 5.32 (s, 1H), 5.03 (dd, *J* = 17.2, 1.6 Hz, 1H), 4.93 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.16 (d, *J* = 8.8 Hz, 1H), 3.77 (s, 3H), 3.62 (s, 3H), 1.63 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 176.8, 144.5, 140.9, 137.0, 133.0, 132.8, 129.9, 128.5, 126.6, 124.7, 121.8, 121.3, 119.9, 114.4, 107.4, 64.8, 60.1, 56.1, 52.6, 32.7, 20.8. HRMS (ESI+) Calcd. For C₂₃H₂₄^{34.9689}ClN₂O₂⁺ ([M+H]⁺): 395.1521, found: 395.1523; C₂₃H₂₄^{36.9659}ClN₂O₂⁺ ([M+H]⁺): 397.1491, found: 397.1495. IR (thin film) ν (cm⁻¹) 3340, 2924, 2867, 1729, 1580, 1486, 1239, 1114, 746. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AS-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.01 and 5.51 min.

Methyl (6*S*,7*R*,9*R*)-9-(4-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*R*,9*R*)-3a)




Yield (66%); 20:1 dr; white solid; m.p. 68-70 °C; $[\alpha]^{30}_D = 107.4$ (*c* 0.50, CH₂Cl₂); HRMS (ESI+) Calcd. For C₂₃H₂₄^{34.9689}ClN₂O₂⁺ ([M+H]⁺): 395.1521, found: 395.1519; C₂₃H₂₄^{36.9659}ClN₂O₂⁺ ([M+H]⁺): 397.1491, found: 397.1490. IR (thin film) ν (cm⁻¹) 3337, 3049, 2947, 1730, 1487, 1457, 1246, 1088, 748. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AS-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.01 and 5.51 min.

Methyl (6*S*,7*S*,9*R*)-9-(4-bromophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3b)



Yield (68%); 19:1 dr; white solid; m.p. 208-210 °C; $[\alpha]^{30}_D = 47.6$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.20 – 7.12 (m, 1H), 7.12 – 7.08 (m, 1H), 6.97 – 6.93 (m, 1H), 6.36 (ddd, *J* = 17.2, 10.4, 7.2 Hz, 1H), 6.17 (s, 1H), 5.79 (s, 1H), 5.20 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.11 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.36 (d, *J* = 9.6 Hz, 1H), 3.61 (s, 3H), 3.59 (s, 3H), 1.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.4, 144.6, 138.2, 136.9, 134.8, 131.4, 129.9, 125.9, 124.9, 122.0, 121.0, 119.9, 118.9, 116.5, 107.2, 65.0, 56.7, 56.5, 51.7, 32.7, 26.5. HRMS (ESI+) Calcd. For C₂₃H₂₄^{78.9183}BrN₂O₂⁺ ([M+H]⁺): 439.1016, found: 439.1013; C₂₃H₂₄^{80.9163}BrN₂O₂⁺ ([M+H]⁺): 441.0995, found: 441.0996. IR (thin film) ν (cm⁻¹) 3333, 3055, 2946, 1729, 1484, 1452, 1244, 1134, 745. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.02 and 6.75 min.


Methyl (6*S*,7*S*,9*R*)-9-(4-fluorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-cd]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3c)



Yield (64%); 17:1 dr; white solid; m.p. 152-154 °C; $[\alpha]^{30}_D = 65.6$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.51 – 7.40 (m, 2H), 7.17 – 7.11 (m, 1H), 7.10 – 7.00 (m, 3H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.36 (ddd, *J* = 17.2, 10.4, 7.2 Hz, 1H), 6.15 (s, 1H), 5.78 (s, 1H), 5.19 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.10 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.34 (d, *J* = 9.6 Hz, 1H), 3.59 (s, 3H), 3.58 (s, 3H), 1.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.5, 162.0 (d, *J* = 241.0 Hz), 141.4, 138.4, 136.9, 134.9, 129.65 (d, *J* = 7.8 Hz), 125.9, 124.9, 122.0, 120.2, 118.9, 116.4, 115.1 (d, *J* = 21.8 Hz), 107.1, 64.9, 56.8, 56.4, 51.7,


32.6, 26.6. ^{19}F NMR (376 MHz, CDCl_3) δ -115.5. HRMS (ESI+) Calcd. For $\text{C}_{23}\text{H}_{24}\text{FN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 379.1816, found: 379.1813. IR (thin film) ν (cm^{-1}) 3322, 3041, 2925, 1730, 1504, 1452, 1221, 1133, 746. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.18 and 5.62 min.

Methyl (6*S*,7*S*,9*R*)-9-(3-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3d)




Yield (62%); 14:1 dr; white solid; m.p. 78-80 °C; $[\alpha]^{30}\text{D} = 39.4$ (*c* 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.53 – 7.49(m, 1H), 7.43 – 7.37 (m, 1H), 7.33 – 7.27 (m, 2H), 7.20 – 7.13 (m, 1H), 7.12-7.08 (m, 1H), 6.96 – 6.93 (m, 1H), 6.37 (ddd, J = 17.2, 10.4, 7.2 Hz, 1H), 6.19 (s, 1H), 5.80 (s, 1H), 5.20 (dd, J = 17.2, 1.6 Hz, 1H), 5.12 (dd, J = 10.4, 1.6 Hz, 1H), 4.36 (d, J = 9.6 Hz, 1H), 3.61 (s, 3H), 3.59 (s, 3H), 1.45 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.4, 147.6, 138.2, 136.9, 134.8, 134.1, 129.6, 128.3, 127.4, 126.3, 125.9, 124.9, 122.0, 119.8, 118.9, 116.5, 107.2, 65.0, 60.1, 56.7, 51.7, 32.7, 26.4. HRMS (ESI+) Calcd. For $\text{C}_{23}\text{H}_{24}^{34.9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 395.1521, found: 395.1516; $\text{C}_{23}\text{H}_{24}^{36.9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 397.1491, found: 397.1503. IR (thin film) ν (cm^{-1}) 3337, 3057, 2922, 1730, 1482, 1456, 1244, 1088, 747. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 4.62 and 4.96 min.

Methyl (6*S*,7*S*,9*R*)-9-(3-bromophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3e)




Yield (70%); 16:1 dr; white solid; m.p. 128-130 °C; $[\alpha]^{30}_D = 52.4$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.69 – 7.66 (m, 1H), 7.49 – 7.44 (m, 2H), 7.26 – 7.23 (m, 1H), 7.21 – 7.15 (m, 1H), 7.14 – 7.10 (m, 1H), 6.99 – 6.94 (m, 1H), 6.39 (ddd, *J* = 17.2, 10.4, 7.2 Hz, 1H), 6.21 (s, 1H), 5.81 (s, 1H), 5.22 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.14 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.38 (d, *J* = 9.6 Hz, 1H), 3.63 (s, 3H), 3.61 (s, 3H), 1.47 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.4, 147.9, 138.2, 136.9, 134.8, 131.2, 130.4, 129.9, 126.8, 126.0, 124.9, 122.4, 122.0, 119.7, 118.9, 116.5, 107.2, 645.0, 56.7, 51.7, 32.7, 26.5, 22.8. HRMS (ESI+) Calcd. For C₂₃H₂₄^{78.9183}BrN₂O₂⁺ ([M+H]⁺): 439.1016, found: 439.1010; C₂₃H₂₄^{80.9163}BrN₂O₂⁺ ([M+H]⁺): 441.0996, found: 441.0996. IR (thin film) ν (cm⁻¹) 3339, 3055, 2944, 1729, 1453, 1423, 1230, 1128, 746. The product was analyzed by HPLC to determine the enantiomeric excess: 98% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 4.68 and 5.15 min.

Methyl (6*S*,7*S*,9*R*)-2,7-dimethyl-9-phenyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3f)




Yield (68%); 15:1 dr; white solid; m.p. 128-130 °C; $[\alpha]^{30}_D = 61.2$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.54 – 7.44 (m, 2H), 7.41 – 7.34 (m, 2H), 7.31 (m, 1H), 7.17 – 7.12 (m, 1H), 7.08 (d, *J* = 7.6 Hz, 1H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.44 – 6.34 (m, 1H), 6.17 (s, 1H), 5.78 (s, 1H), 5.19 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.10 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.36 (d, *J* = 9.6 Hz, 1H), 3.59 (s, 3H), 3.58 (s, 3H), 1.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.5, 142.0, 138.4, 136.9, 134.9, 128.3, 128.1, 127.3, 126.0, 125.1, 121.9, 120.5, 118.8, 116.3, 107.1, 65.0, 57.1, 56.7, 51.7, 32.6, 26.5. HRMS (ESI+) Calcd. For C₂₃H₂₅N₂O₂⁺ ([M+H]⁺): 361.1911, found: 361.1907. IR (thin film) ν (cm⁻¹) 3341, 2923, 2854, 1730, 1452, 1420, 1231, 1133, 746. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.27 and 5.88 min.

Methyl (6S,7S,9R)-2,7-dimethyl-9-(*p*-tolyl)-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6S,7S,9R)-3g)



Yield (60%); 12:1 dr; white solid; m.p. 118-120 °C; $[\alpha]^{30}_D = 86.6$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, *J* = 8.4 Hz, 2H), 7.18 (d, *J* = 8.4 Hz, 2H), 7.16 – 7.13 (m, 1H), 7.09 (d, *J* = 7.2 Hz, 1H), 6.95 (d, *J* = 7.2 Hz, 1H), 6.39 (ddd, *J* = 17.2, 10.4, 7.2 Hz, 1H), 6.20 (s, 1H), 5.75 (s, 1H), 5.20 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.10 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.35 (d, *J* = 9.6 Hz, 1H), 3.60 (s, 6H), 2.38 (s, 3H), 1.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.5, 142.7, 138.5, 136.9, 136.8, 135.0, 129.0, 128.1, 126.0, 125.1, 121.9, 120.6, 118.7, 116.3, 107.1, 64.9, 56.8, 51.6, 32.6, 26.5, 21.2, 14.1. HRMS (ESI+) Calcd. For C₂₄H₂₇N₂O₂⁺ ([M+H]⁺): 375.2067, found: 375.2068. IR (thin film) ν (cm⁻¹) 3351, 2944, 2854, 1731, 1601, 1484, 1220, 1084, 751. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.62 and 6.57 min.


Methyl (6S,7S,9R)-9-(4-methoxyphenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6S,7S,9R)-3h)



Yield (66%); 18:1 dr; white solid; m.p. 126-128 °C; $[\alpha]^{30}_D = 85.0$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.45 – 7.39 (m, 2H), 7.18 – 7.12 (m, 1H), 7.09 (d, *J* = 7.2 Hz, 1H), 6.94 (d, *J* = 7.0 Hz, 1H), 6.93 – 6.87 (m, 2H), 6.38 (ddd, *J* = 17.2, 10.4, 7.2 Hz, 1H), 6.19 (s, 1H), 5.72 (s, 1H), 5.19 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.09 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.33 (d, *J* = 9.6 Hz, 1H), 3.83 (s, 3H), 3.60 (s, 3H), 3.60 (s, 3H), 1.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.6, 158.8, 138.6, 138.0, 137.0,


135.0, 129.2, 126.0, 125.0, 121.9, 120.6, 118.78, 116.2, 113.7, 107.1, 64.9, 56.9, 56.5, 55.3, 51.7, 32.6, 26.7. HRMS (ESI⁺) Calcd. For C₂₄H₂₇N₂O₃⁺ ([M+H]⁺): 391.2016, found: 391.2019. IR (thin film) ν (cm⁻¹) 3342, 2946, 2863, 1730, 1609, 1510, 1243, 1177, 745. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.95 and 9.29 min.

Methyl (6*S*,7*S*,9*R*)-2,7-dimethyl-9-(*m*-tolyl)-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3i)




Yield (58%); 15:1 dr; white solid; m.p. 124–126°C; [α]³⁰_D = 106.6 (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.26 (m, 3H), 7.18 – 7.08 (m, 3H), 6.95 (d, *J* = 7.2 Hz, 1H), 6.40 (ddd, *J* = 17.2, 10.8, 7.2 Hz, 1H), 6.19 (s, 1H), 5.74 (s, 1H), 5.21 (dd, *J* = 17.2, 2.0 Hz, 1H), 5.11 (dd, *J* = 10.8, 2.0 Hz, 1H), 4.37 (d, *J* = 9.6 Hz, 1H), 3.61 (s, 3H), 3.60 (s, 3H), 2.38 (s, 3H), 1.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.5, 145.4, 138.5, 137.9, 136.9, 135.0, 128.9, 128.2, 128.0, 126.0, 125.2, 121.9, 120.5, 118.8, 116.3, 107.1, 65.0, 57.1, 56.8, 51.7, 32.6, 26.5, 21.5. HRMS (ESI⁺) Calcd. For C₂₄H₂₇N₂O₂⁺ ([M+H]⁺): 375.2067, found: 375.2069. IR (thin film) ν (cm⁻¹) 3335, 2924, 2863, 1730, 1606, 1453, 1241, 1131, 746. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak IC, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 8.20 and 9.78 min.

Methyl (6*S*,7*S*,9*R*)-9-(3-methoxyphenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3j)



Yield (61%); 16:1 dr; white solid; m.p. 122-124 °C; $[\alpha]^{30}_D = 80.6$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.30 – 7.25 (m, 1H), 7.16 – 7.12 (m, 1H), 7.10 – 7.05 (m, 3H), 6.93 (d, *J* = 7.0 Hz, 1H), 6.86 – 6.82 (m, 1H), 6.37 (ddd, *J* = 17.2, 10.4, 7.2 Hz, 1H), 6.22 (s, 1H), 5.76 (s, 1H), 5.18 (dd, *J* = 17.2, 2.0 Hz, 1H), 5.09 (dd, *J* = 10.4, 2.0 Hz, 1H), 4.36 (d, *J* = 9.6 Hz, 1H), 3.80 (s, 3H), 3.58 (s, 6H), 1.43 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.5, 159.6, 147.1, 138.4, 136.9, 134.9, 129.3, 126.0, 125.1, 121.9, 120.5, 120.2, 118.7, 116.4, 113.6, 112.7, 107.1, 65.0, 57.0, 56.7, 55.2, 51.7, 32.6, 26.4. HRMS (ESI+) Calcd. For C₂₄H₂₇N₂O₃⁺ ([M+H]⁺): 391.2016, found: 391.2019. IR (thin film) ν (cm⁻¹) 3339, 2933, 2865, 1730, 1602, 1455, 1244, 1152, 1045, 748. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.87 and 6.67 min.


Methyl (6*S*,7*S*,9*R*)-2,7-dimethyl-9-(*o*-tolyl)-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3k)



Yield (63%); 11:1 dr; white solid; m.p. 88-90 °C; $[\alpha]^{30}_D = 138.6$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.50 – 7.40 (m, 1H), 7.22 – 7.19 (m, 3H), 7.18 – 7.13 (m, 1H), 7.09 (d, *J* = 7.8 Hz, 1H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.35 (ddd, *J* = 17.2, 10.4, 7.2 Hz, 1H), 6.06 (s, 1H), 5.98 (s, 1H), 5.20 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.10 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.62 – 4.30 (m, 1H), 3.62 (s, 3H), 3.58 (s, 3H), 2.48 (s, 3H), 1.43 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.4, 143.2, 138.1, 137.1, 135.1, 130.1, 128.4, 127.0, 126.2, 125.5, 125.2, 120.0, 120.5, 119.4, 118.6, 116.5, 107.2, 65.5, 60.4, 56.1, 51.7, 32.6, 25.5, 19.5. HRMS (ESI+) Calcd. For C₂₄H₂₇N₂O₂⁺ ([M+H]⁺): 375.2067, found: 375.2068. IR (thin film) ν (cm⁻¹) 3358, 2919, 2850, 1733, 1633, 1454, 1241, 1114, 751. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 4.24 and 5.37 min.


Methyl (6*S*,7*S*,9*R*)-9-(2-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino

[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3l)



Yield (66%); 15:1 dr; white solid; m.p. 148–150 °C; $[\alpha]^{30}_D = 83.2$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.59 – 7.56 (m, 1H), 7.44 – 7.40 (m, 1H), 7.29 – 7.26 (m, 1H), 7.26 – 7.21 (m, 1H), 7.19 – 7.14 (m, 1H), 7.10 (d, *J* = 7.4 Hz, 1H), 6.95 (d, *J* = 7.2 Hz, 1H), 6.44 – 6.30 (m, 1H), 6.35 (s, 1H), 6.18 (brs, 1H), 5.22 (dd, *J* = 17.2, 2.0 Hz, 1H), 5.14 (dd, *J* = 10.4, 2.0 Hz, 1H), 4.47 (d, *J* = 9.6 Hz, 1H), 3.64 (s, 3H), 3.61 (s, 3H), 1.45 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.2, 143.0, 137.9, 136.9, 134.7, 132.9, 130.3, 129.2, 128.2, 127.2, 125.3, 122.0, 119.5, 118.7, 116.8, 107.3, 65.4, 56.2, 52.6, 51.8, 32.7, 25.7. HRMS (ESI+) Calcd. For C₂₃H₂₄^{34.9689}ClN₂O₂⁺ ([M+H]⁺): 395.1521, found: 395.1518; C₂₃H₂₄^{36.9659}ClN₂O₂⁺ ([M+H]⁺): 397.1491, found: 397.1496. IR (thin film) ν (cm⁻¹) 3334, 2925, 2853, 1724, 1633, 1451, 1250, 1119, 746. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.05 and 6.01 min.


Methyl (6*S*,7*S*,9*R*)-9-(2-bromophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3m)



Yield (64%); 15:1 dr; white solid; m.p. 162–164 °C; $[\alpha]^{30}_D = 70.6$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.63 – 7.60 (m, 1H), 7.58 – 7.55 (m, 1H), 7.35 – 7.28 (m, 1H), 7.20 – 7.14 (m, 2H), 7.11 (d, *J* = 7.6 Hz, 1H), 6.97 (d, *J* = 7.2 Hz, 1H), 6.44 – 6.34 (m, 1H), 6.33 (s, 1H), 6.20 (s, 1H), 5.23 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.14 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.44 (d, *J* = 9.6 Hz, 1H), 3.65 (s, 3H), 3.61 (s, 3H), 1.47 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.2, 144.9, 138.1, 136.9, 134.7, 132.3, 130.6, 128.6, 127.8, 125.5, 125.2, 123.3, 122.0, 119.2, 118.8, 116.6, 107.2, 65.2, 56.0, 55.0, 51.8, 32.7, 26.0.


HRMS (ESI+) Calcd. For $C_{23}H_{24}^{78,9183}\text{BrN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 439.1016, found: 439.1017; $C_{23}H_{24}^{80,9163}\text{BrN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 441.0996, found: 441.1000. IR (thin film) ν (cm^{-1}) 3334, 3071, 2926, 1729, 1633, 1456, 1246, 1134, 746. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.01 and 5.78 min.

Methyl (6*S*,7*S*,9*S*)-2,7-dimethyl-9-(thiophen-2-yl)-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*S*)-3n)




Yield (58%); 14:1 dr; white solid; m.p. 56–58 °C; $[\alpha]^{30}_{\text{D}} = 83.4$ (c 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.26 – 7.24 (m, 1H), 7.18 – 7.16 (m, 1H), 7.16 – 7.12 (m, 1H), 7.11 – 7.07 (m, 1H), 7.03 – 6.99 (m, 1H), 6.94 (d, J = 7.2 Hz, 1H), 6.51 (s, 1H), 6.38 (ddd, J = 17.2, 10.4, 7.2 Hz, 1H), 6.22 (s, 1H), 5.20 (dd, J = 17.2, 2.0 Hz, 1H), 5.11 (dd, J = 10.4, 2.0 Hz, 1H), 4.31 (d, J = 9.6 Hz, 1H), 3.64 (s, 3H), 3.59 (s, 3H), 1.45 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.5, 150.1, 138.3, 137.0, 134.8, 126.2, 126.0, 124.5, 124.4, 124.0, 121.9, 119.4, 118.9, 116.4, 107.2, 64.8, 56.9, 52.5, 51.7, 32.7, 26.5. HRMS (ESI+) Calcd. For $C_{21}\text{H}_{23}\text{N}_2\text{O}_2\text{S}^+$ ($[\text{M}+\text{H}]^+$): 367.1475, found: 367.1472. IR (thin film) ν (cm^{-1}) 3342, 3065, 2945, 1730, 1606, 1454, 1238, 1125, 750. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.65 and 7.80 min.

Methyl (6*R*,7*R*,9*R*)-2,7-dimethyl-9-(thiophen-2-yl)-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*R*,9*R*)-3n)




Yield (60%); 14:1 dr; white solid; m.p. 56-58 °C; $[\alpha]^{30}_D = -86.1$ (*c* 0.50, CH₂Cl₂); HRMS (ESI+) Calcd. For C₂₁H₂₃N₂O₂S⁺ ([M+H]⁺): 367.1475, found: 367.1473. IR (thin film) ν (cm⁻¹) 3340, 3061, 2945, 1730, 1606, 1452, 1238, 1125, 744. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.65 and 7.80 min.

Methyl (6*R*,7*S*,9*R*)-2,7-dimethyl-9-(thiophen-2-yl)-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*S*,9*R*)-3n)




Yield (45%); 10:1 dr; white solid; m.p. 54-56 °C; $[\alpha]^{30}_D = -93.6$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.27 – 7.26 (m, 1H), 7.19 – 7.09 (m, 3H), 7.05 – 6.87 (m, 2H), 6.51 (s, 1H), 6.43 – 6.27 (m, 1H), 5.75 (s, 1H), 5.04 (dd, *J* = 17.2, 1.6 Hz, 1H), 4.92 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.14 (d, *J* = 8.8 Hz, 1H), 3.78 (s, 3H), 3.66 (s, 3H), 1.63 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 176.7, 150.07, 140.87, 137.1, 132.8, 126.8, 125.7, 124.9, 124.2, 124.1, 121.7, 121.2, 119.8, 114.3, 107.4, 64.8, 60.0, 52.6, 51.8, 32.8, 20.7. HRMS (ESI+) Calcd. For C₂₁H₂₃N₂O₂S⁺ ([M+H]⁺): 367.1475, found: 367.1472. IR (thin film) ν (cm⁻¹) 3340, 3065, 2944, 1729, 1605, 1454, 1240, 1125, 750. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 280 nm); t_r = 6.01 and 17.97 min.

Methyl (6*S*,7*R*,9*S*)-2,7-dimethyl-9-(thiophen-2-yl)-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*R*,9*S*)-3n)




Yield (52%); 10:1 dr; white solid; m.p. 54–56 °C; $[\alpha]^{30}_D = 96.0$ (*c* 0.50, CH₂Cl₂); HRMS (ESI+) Calcd. For C₂₁H₂₃N₂O₂S⁺ ([M+H]⁺): 367.1475, found: 367.1473. IR (thin film) ν (cm⁻¹) 3340, 3060, 2944, 1730, 1606, 1452, 1238, 1125, 741. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 280 nm); t_r = 6.01 and 17.97 min.

Methyl (6*S*,7*S*,9*S*)-2,7-dimethyl-(furan-2-yl)-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*S*)-3o)




Yield (55%); 10:1 dr; white solid; m.p. 76–78 °C; $[\alpha]^{30}_D = 110.2$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.44 – 7.41 (m, 1H), 7.26 – 7.25 (m, 1H), 7.20 – 7.04 (m, 2H), 6.96 – 6.85 (m, 1H), 6.48 (s, 1H), 6.42 – 6.30 (m, 2H), 6.20 (ddd, *J* = 17.2, 10.0, 8.6 Hz, 1H), 5.56 (s, 1H), 5.29 (dd, *J* = 10.0, 2.0 Hz, 1H), 5.09 (dd, *J* = 17.2, 2.0 Hz, 1H), 4.09 (d, *J* = 8.4 Hz, 1H), 3.68 (s, 3H), 3.50 (s, 3H), 1.52 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.7, 156.3, 141.7, 137.5, 137.1, 133.0, 125.3, 125.2, 121.7, 120.0, 118.7, 118.4, 110.1, 107.8, 106.3, 66.0, 59.0, 51.8, 49.7, 32.8, 20.1. HRMS (ESI+) Calcd. For C₂₁H₂₃N₂O₃⁺ ([M+H]⁺): 351.1703, found: 351.1699. IR (thin film) ν (cm⁻¹) 3342, 3117, 2925, 1736, 1585, 1455, 1373, 1247, 1148, 750. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 11.62 and 13.82 min.

Methyl (6*S*,7*S*,9*R*)-2,7-dimethyl-9-propyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3p)



Yield (44%); 11:1 dr; white solid; m.p. 68-70 °C; $[\alpha]^{30}_D = 71.0$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.16 – 7.09 (m, 2H), 6.85 – 6.81 (m, 1H), 6.69 (s, 1H), 6.31 – 6.16 (m, 1H), 5.23 (s, 1H), 5.21 – 5.17 (m, 1H), 4.76 – 4.68 (m, 2H), 3.70 (s, 3H), 3.68 (s, 3H), 1.95 – 1.85 (m, 1H), 1.67 – 1.61 (m, 1H), 1.50 – 1.41 (m, 3H), 1.00 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 174.9, 136.8, 135.7, 134.3, 127.3, 122.5, 122.1, 121.6, 118.5, 117.3), 107.5, 66.6, 52.5, 51.5, 49.8, 37.6, 32.7, 21.5, 19.1, 14.2. HRMS (ESI+) Calcd. For C₂₀H₂₇N₂O₂⁺ ([M+H]⁺): 327.2067, found: 327.2064. IR (thin film) ν (cm⁻¹) 3345, 2926, 2867, 1735, 1673, 1495, 1231, 1146, 748. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.39 and 6.18 min.


(6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-2-methyl-6-vinyl-2',4',5',6,8,9-hexahydro-2'H-spiro[azepino[3,4,5-*cd*]indole-7,3'-furan]-2'-one ((6*S*,7*S*,9*R*)-3q)



Yield (62%); 10:1 dr; white solid; m.p. 134-136 °C; $[\alpha]^{30}_D = 63.2$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, *J* = 8.4 Hz, 2H), 7.34 (d, *J* = 8.4 Hz, 2H), 7.23 – 7.17 (m, 2H), 6.93 – 6.87 (m, 1H), 6.76 (ddd, *J* = 17.2, 10.4, 4.4 Hz, 1H), 5.95 (s, 1H), 5.84 (s, 1H), 5.35 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.90 (dd, *J* = 17.2, 1.6 Hz, 1H), 4.30 – 4.20 (m, 1H), 4.12 – 4.02 (m, 1H), 3.86 – 3.78 (m, 1H), 3.64 (s, 3H), 2.37 – 2.19 (m, 1H), 1.95 – 1.88 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 178.8, 142.5, 137.6, 137.3, 132.9, 132.0, 129.7, 128.3, 127.4, 126.5, 122.4, 120.8, 119.2, 117.6, 108.4, 65.7, 65.3, 55.9, 52.8, 39.6, 32.7, 29.8. HRMS (ESI+) Calcd. For C₂₃H₂₂^{34,9689}ClN₂O₂⁺ ([M+H]⁺): 393.1364, found: 393.1365; C₂₃H₂₂^{36,9659}ClN₂O₂⁺ ([M+H]⁺): 395.1334, found: 395.1335. IR (thin film) ν (cm⁻¹) 3357, 2922, 2851, 1727, 1632, 1514, 1246, 1123, 811. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 9.19 and 11.26 min.


Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-7-ethyl-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino

[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3r)



Yield (66%); 20:1 dr; white solid; m.p. 114–116 °C; $[\alpha]^{30}_D = 103.8$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 7.21 – 7.13 (m, 1H), 7.08 (d, *J* = 7.4 Hz, 1H), 7.01 (d, *J* = 7.2 Hz, 1H), 6.48 – 6.36 (m, 1H), 6.21 (s, 1H), 5.68 (s, 1H), 5.21 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.02 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.20 (d, *J* = 9.6 Hz, 1H), 3.60 (s, 3H), 3.55 (s, 3H), 2.01 – 1.90 (m, 1H), 1.75 – 1.68 (m, 1H), 0.95 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 174.4, 145.1, 139.8, 136.9, 135.4, 133.0, 129.8, 128.5, 126.4, 124.1, 121.9, 119.6, 118.4, 114.9, 106.8, 67.7, 57.6, 56.1, 51.4, 33.8, 32.7, 8.6. HRMS (ESI+) Calcd. For C₂₄H₂₆^{34,9689}ClN₂O₂⁺ ([M+H]⁺): 409.1677, found: 409.1672; C₂₄H₂₆^{36,9659}ClN₂O₂⁺ ([M+H]⁺): 411.1647, found: 411.1657. IR (thin film) ν (cm⁻¹) 3339, 2943, 2878, 1729, 1632, 1487, 1224, 1137, 745. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.40 and 7.37 min.


Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-7-propyl-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3s)



Yield (63%); 20:1 dr; white solid; m.p. 138–140 °C; $[\alpha]^{30}_D = 107.8$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.43 (m, 2H), 7.37 – 7.29 (m, 2H), 7.18 – 7.13 (m, 1H), 7.10 – 7.06 (m, 1H), 6.99 (d, *J* = 6.8 Hz, 1H), 6.48 – 6.36 (m, 1H), 6.20 (s, 1H), 5.69 (s, 1H), 5.19 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.02 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.19 (d, *J* = 9.6 Hz, 1H), 3.60 (s, 3H), 3.53 (s, 3H), 1.91 (dd, *J* = 12.8, 4.8 Hz, 1H), 1.60 (dd, *J* = 25.2, 4.8 Hz, 1H), 1.52 – 1.40 (m, 1H), 1.31 – 1.24 (m, 1H), 0.89 (t, *J*

= 7.2 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 174.6, 145.1, 139.8, 136.9, 135.4, 133.0, 129.8, 128.5, 126.4, 124.1, 121.9, 119.6, 118.5, 115.0, 106.8, 67.3, 57.5, 56.7, 51.4, 43.2, 32.7, 17.4, 14.2. HRMS (ESI+) Calcd. For $\text{C}_{25}\text{H}_{28}^{34.9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 423.1834, found: 423.1835; $\text{C}_{25}\text{H}_{28}^{36.9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 425.1804, found: 425.1807. IR (thin film) ν (cm^{-1}) 3340, 2944, 2877, 1729, 1593, 1455, 1241, 1082, 752. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.24 and 6.89 min.


Ethyl (6*S*,7*S*,9*R*)-7-allyl-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3t)



Yield (66%); 20:1 dr; white solid; m.p. 54–56 °C; $[\alpha]^{30}_D = 74.6$ (c 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.44 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.17 – 7.10 (m, 1H), 7.06 (d, J = 7.2 Hz, 1H), 6.96 (d, J = 7.2 Hz, 1H), 6.48 – 6.38 (m, 1H), 6.21 (s, 1H), 5.78 (s, 1H), 5.85 – 5.70 (m, 1H), 5.20 (dd, J = 17.2, 1.6 Hz, 1H), 5.16 – 5.12 (m, 2H), 5.05 (dd, J = 10.4, 1.6 Hz, 1H), 4.17 (d, J = 9.6 Hz, 1H), 4.02 – 3.94 (m, 2H), 3.59 (s, 3H), 2.67 (dd, J = 13.6, 6.4 Hz, 1H), 2.43 (dd, J = 13.6, 8.4 Hz, 1H), 0.95 (t, J = 7.2 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 173.5, 145.2, 139.6, 136.9, 135.2, 132.9, 132.4, 129.8, 128.5, 126.4, 124.2, 121.8, 119.8, 119.4, 118.4, 115.6, 106.9, 66.5, 60.3, 57.2, 44.6, 32.7, 14.0. HRMS (ESI+) Calcd. For $\text{C}_{26}\text{H}_{28}^{34.9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 435.1834, found: 435.1824; $\text{C}_{26}\text{H}_{28}^{36.9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 437.1804, found: 437.1806. IR (thin film) ν (cm^{-1}) 3334, , 2931, 2862, 1726, 1634, 1487, 1204, 1138, 748. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.99 and 8.53 min.


Ethyl (6*R*,7*R*,9*S*)-7-allyl-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino

[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*R*,9*S*)-3t)



Yield (60%); 19:1 dr; white solid; m.p. 54-56 °C; $[\alpha]^{30}_D = -72.4$ (*c* 0.50, CH₂Cl₂); HRMS (ESI+) Calcd. For C₂₆H₂₈^{34.9689}ClN₂O₂⁺ ([M+H]⁺): 435.1834, found: 435.1829; C₂₆H₂₈^{36.9659}ClN₂O₂⁺ ([M+H]⁺): 437.1804, found: 437.1811. IR (thin film) ν (cm⁻¹) 3344, 2926, 2855, 1729, 1635, 1487, 1215, 1162, 748. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.99 and 8.53 min.


Ethyl (6*R*,7*S*,9*S*)-7-allyl-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*S*,9*S*)-3t)



Yield (60%); 20:1 dr; white solid; m.p. 140-142 °C; $[\alpha]^{30}_D = -79.2$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J* = 8.4 Hz, 2H), 7.32 (d, *J* = 8.4 Hz, 2H), 7.22 – 7.11 (m, 2H), 6.97 (d, *J* = 6.0 Hz, 1H), 6.45 – 6.28 (m, 1H), 6.24 (s, 1H), 5.87 – 5.67 (m, 1H), 5.37 (s, 1H), 5.14 – 5.09 (m, 1H), 5.14 – 5.08 (m, 1H), 5.03 (dd, *J* = 17.2, 2.0 Hz, 1H), 4.92 (dd, *J* = 10.4, 2.0 Hz, 1H), 4.26 – 4.18 (m, 2H), 4.17 (d, *J* = 8.8 Hz, 1H), 3.63 (s, 3H), 3.10 (dd, *J* = 15.2, 6.4 Hz, 1H), 2.52 (dd, *J* = 15.2, 7.6 Hz, 1H), 1.33 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 174.7, 144.3, 140.8, 137.0, 133.5, 133.1, 132.8, 129.9, 128.5, 126.5, 124.6, 121.7, 121.0, 119.8, 118.2, 114.4, 107.5, 68.1, 61.6, 60.1, 55.8, 37.9, 32.7, 14.3. HRMS (ESI+) Calcd. For C₂₆H₂₈^{34.9689}ClN₂O₂⁺ ([M+H]⁺): 435.1834, found: 435.1830; C₂₆H₂₈^{36.9659}ClN₂O₂⁺ ([M+H]⁺): 437.1804, found: 437.1808. IR (thin film) ν (cm⁻¹) 3335, 2925, 2855, 1726, 1634, 1487, 1204, 1138, 748. The product was analyzed by HPLC to determine the


enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.55 and 8.68 min.

Ethyl (6*S*,7*R*,9*R*)-7-allyl-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*R*,9*R*)-3t)



Yield (62%); 20:1 dr; white solid; m.p. 140-142 °C; $[\alpha]^{30}_{\text{D}} = 79.6$ (*c* 0.50, CH_2Cl_2); HRMS (ESI+) Calcd. For $\text{C}_{26}\text{H}_{28}^{34,9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 435.1834, found: 435.1832; $\text{C}_{26}\text{H}_{28}^{36,9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 437.1804, found: 437.1807. IR (thin film) ν (cm^{-1}) 3348, 2976, 2872, 1728, 1635, 1469, 1215, 1159, 748. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.55 and 8.68 min.


Methyl (6*S*,7*R*,9*R*)-7-(*tert*-butoxymethyl)-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*R*,9*R*)-3u)



Yield (65%); 20:1 dr; white solid; m.p. 148-150 °C; $[\alpha]^{30}_{\text{D}} = 51.6$ (*c* 0.50, CH_2Cl_2); ¹H NMR (400 MHz, CDCl_3) δ 7.48 (d, *J* = 8.4 Hz, 2H), 7.32 (d, *J* = 8.4 Hz, 2H), 7.17 – 7.09 (m, 1H), 7.06 (d, *J* = 7.6 Hz, 1H), 6.97 (d, *J* = 7.2 Hz, 1H), 6.45 – 6.33 (m, 1H), 6.22 (s, 1H), 5.85 (s, 1H), 5.17 (dd, *J* = 17.2, 1.6 Hz, 1H), 4.99 (dd, *J* = 10.0, 2.0 Hz, 1H), 4.23 (d, *J* = 9.2 Hz, 1H), 3.59 (s, 1H), 3.51 (s, 1H), 3.63 – 3.56 (m, 1H), 3.53 – 3.45 (m, 1H), 1.11 (s, 9H). ¹³C NMR (101 MHz, CDCl_3) δ 174.0, 145.5, 139.8, 136.9, 135.1, 132.8, 129.9, 128.4, 126.7, 124.1, 121.8, 119.5, 118.4, 115.0, 106.9, 73.2, 68.2, 67.6,


57.5, 55.6, 51.4, 32.7, 27.4. HRMS (ESI+) Calcd. For $C_{27}H_{32}^{34.9689}ClN_2O_3^+$ ($[M+H]^+$): 467.2096, found: 467.2097; $C_{27}H_{32}^{36.9659}ClN_2O_3^+$ ($[M+H]^+$): 469.2066, found: 469.2061. IR (thin film) ν (cm⁻¹) 3334, 2973, 2873, 1743, 1604, 1487, 1196, 1090, 746. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.38 and 6.64 min.

Methyl (6*R*,7*S*,9*S*)-7-(*tert*-butoxymethyl)-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*S*,9*S*)-3u)



Yield (61%); 20:1 dr; white solid; m.p. 148-150 °C; $[\alpha]^{30}_D$ = -55.0 (*c* 0.50, CH₂Cl₂); HRMS (ESI+) Calcd. For $C_{27}H_{32}^{34.9689}ClN_2O_3^+$ ($[M+H]^+$): 467.2096, found: 467.2103; $C_{27}H_{32}^{36.9659}ClN_2O_3^+$ ($[M+H]^+$): 469.2066, found: 469.2067. IR (thin film) ν (cm⁻¹) 3333, 2973, 2875, 1743, 1630, 1488, 1197, 1091, 747. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.38 and 6.64 min.


Methyl (6*R*,7*R*,9*S*)-7-(*tert*-butoxymethyl)-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*R*,9*S*)-3u)



Yield (60%); 20:1 dr; white solid; m.p. 178-180 °C; $[\alpha]^{30}_D$ = -81.6 (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, *J* = 8.4 Hz, 2H), 7.32 (d, *J* = 8.4 Hz, 2H), 7.19 – 7.05 (m, 2H), 6.93 (d, *J* = 6.4 Hz, 1H), 6.40 – 6.30 (m, 1H), 6.23 (s, 1H), 5.38 (s, 1H), 5.04 (dd, *J* = 17.2, 2.0 Hz, 1H), 4.90 (dd, *J* =


10.4, 2.0 Hz, 1H), 4.10 (d, J = 8.8 Hz, 1H), 4.03 (d, J = 9.2 Hz, 1H), 3.75 (s, 3H), 3.66 (d, J = 9.2 Hz, 1H), 3.62 (s, 3H), 1.10 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 174.5, 144.6, 140.8, 137.1, 132.9, 132.7, 130.1, 128., 126.5, 124.7, 121.6, 120.7, 120.2, 114.1, 107.4, 72.9, 69.6, 62.5, 57.2, 55.6, 52.3, 32.7, 27.5. HRMS (ESI $^+$) Calcd. For $\text{C}_{27}\text{H}_{32}^{34.9689}\text{ClN}_2\text{O}_3^+$ ($[\text{M}+\text{H}]^+$): 467.2096, found: 467.2095; $\text{C}_{27}\text{H}_{32}^{36.9659}\text{ClN}_2\text{O}_3^+$ ($[\text{M}+\text{H}]^+$): 469.2066, found: 469.2076. IR (thin film) ν (cm^{-1}) 3341, 2975, 2879, 1739, 1631, 1473, 1221, 1092, 748. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 4.01 and 10.64 min.

Methyl (6*S*,7*S*,9*R*)-7-(*tert*-butoxymethyl)-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3u)




Yield (62%); 19:1 dr; white solid; m.p. 178-180 °C; $[\alpha]^{30}_D$ = 84.8 (c 0.50, CH_2Cl_2); HRMS (ESI $^+$) Calcd. For $\text{C}_{27}\text{H}_{32}^{34.9689}\text{ClN}_2\text{O}_3^+$ ($[\text{M}+\text{H}]^+$): 467.2096, found: 467.2092; $\text{C}_{27}\text{H}_{32}^{36.9659}\text{ClN}_2\text{O}_3^+$ ($[\text{M}+\text{H}]^+$): 469.2066, found: 469.2068. IR (thin film) ν (cm^{-1}) 3342, 2973, 2885, 1741, 1631, 1487, 1236, 1090, 747. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 4.01 and 10.64 min.

Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-7-(3-methoxy-3-oxopropyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3v)




Yield (58%); 20:1 dr; yellow liquid; $[\alpha]^{30}_D = 72.0$ (c 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.47 – 7.41 (m, 2H), 7.37 – 7.30 (m, 2H), 7.17 – 7.12 (m, 1H), 7.09 (d, J = 7.2 Hz, 1H), 6.95 (d, J = 7.0 Hz, 1H), 6.46 – 6.31 (m, 1H), 6.19 (s, 1H), 5.78 (s, 1H), 5.20 (dd, J = 17.2, 1.6 Hz, 1H), 5.09 (dd, J = 10.4, 1.6 Hz, 1H), 4.26 (d, J = 8.4 Hz, 1H), 3.63 (s, 3H), 3.60 (s, 3H), 3.55 (s, 3H), 2.52 – 2.32 (m, 2H), 2.22 (ddd, J = 13.6, 10.4, 6.4 Hz, 1H), 2.03 (ddd, J = 10.4, 6.4, 4.4 Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 173.9, 173.4, 134.4, 133.0, 129.7, 128.5, 126.1, 122.0, 119.3, 116.4, 107.2, 67.2, 56.8, 56.3, 51.7, 32.7, 29.1. HRMS (ESI $^+$) Calcd. For $\text{C}_{26}\text{H}_{28}^{34.9689}\text{ClN}_2\text{O}_4^+$ ($[\text{M}+\text{H}]^+$): 467.1732, found: 467.1722; $\text{C}_{26}\text{H}_{28}^{36.9659}\text{ClN}_2\text{O}_4^+$ ($[\text{M}+\text{H}]^+$): 469.1702, found: 469.1709. IR (thin film) ν (cm^{-1}) 3357, 2924, 2852, 1736, 1591, 1453, 1202, 1086, 752. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 20/80, flow rate 1.0 mL/min, λ = 230 nm); t_r = 8.04 and 9.56 min.

Methyl (6*R*,7*R*,9*S*)-9-(4-chlorophenyl)-7-(3-methoxy-3-oxopropyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*R*,9*S*)-3v)




Yield (52%); 19:1 dr; yellow liquid; $[\alpha]^{30}_D = -73.4$ (c 0.50, CH_2Cl_2); HRMS (ESI $^+$) Calcd. For $\text{C}_{26}\text{H}_{28}^{34.9689}\text{ClN}_2\text{O}_4^+$ ($[\text{M}+\text{H}]^+$): 467.1732, found: 467.1735; $\text{C}_{26}\text{H}_{28}^{36.9659}\text{ClN}_2\text{O}_4^+$ ($[\text{M}+\text{H}]^+$): 469.1702, found: 469.1707. IR (thin film) ν (cm^{-1}) 3356, 2924, 2852, 1735, 1592, 1488, 1201, 1085, 751. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 20/80, flow rate 1.0 mL/min, λ = 230 nm); t_r = 8.04 and 9.56 min.

Methyl (6*R*,7*S*,9*S*)-9-(4-chlorophenyl)-7-(3-methoxy-3-oxopropyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*S*,9*S*)-3v)




Yield (54%); 20:1 dr; white solid; m.p. 68-70 °C; $[\alpha]^{30}_D = -225.4$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 7.20 – 7.09 (m, 2H), 6.96 – 6.92 (m, 1H), 6.40 – 6.26 (m, 1H), 6.21 (s, 1H), 5.22 (s, 1H), 5.02 (dd, *J* = 17.2, 2.0 Hz, 1H), 4.93 (dd, *J* = 10.4, 2.0 Hz, 1H), 4.16 (d, *J* = 8.8 Hz, 1H), 3.77 (s, 3H), 3.63 (s, 3H), 3.60 (s, 3H), 2.62 – 2.52 (m, 1H), 2.50 – 2.39 (m, 1H), 2.23 – 2.07 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 175.0, 173.2, 143.9, 140.6, 137.0, 133.2, 132.4, 129.8, 128.6, 126.6, 124.6, 121.9, 120.9, 119.7, 114.6, 107.6, 67.9, 60.1, 55.6, 52.7, 51.7, 32.7, 29.8, 28.6. HRMS (ESI+) Calcd. For C₂₆H₂₈^{34.9689}ClN₂O₄⁺ ([M+H]⁺): 467.1732, found: 467.1729; C₂₆H₂₈^{36.9659}ClN₂O₄⁺ ([M+H]⁺): 469.1702, found: 469.1702. IR (thin film) ν (cm⁻¹) 3347, 2949, 2852, 1735, 1589, 1457, 1171, 1085, 754. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 20/80, flow rate 1.0 mL/min, λ = 230 nm); t_r = 8.53 and 10.34 min.

Methyl (6*S*,7*R*,9*R*)-9-(4-chlorophenyl)-7-(3-methoxy-3-oxopropyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*R*,9*R*)-3v)




Yield (55%); 18:1 dr; white solid; m.p. 68-70 °C; $[\alpha]^{30}_D = 222.5$ (*c* 0.50, CH₂Cl₂); HRMS (ESI+) Calcd. For C₂₆H₂₈^{34.9689}ClN₂O₄⁺ ([M+H]⁺): 467.1732, found: 467.1742; C₂₆H₂₈^{36.9659}ClN₂O₄⁺ ([M+H]⁺): 469.1702, found: 469.1709. IR (thin film) ν (cm⁻¹) 3357, 2949, 2854, 1735, 1591, 1485, 1240, 1083, 753. The product was analyzed by HPLC to determine the enantiomeric excess: 97% ee (Chiralpak AD-H, *i*-propanol /hexane = 20/80, flow rate 1.0 mL/min, λ = 230 nm); t_r = 8.53 and 10.34 min.

Methyl (6S,7S,9R)-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2H-azepino[3,4,5-cd]indole-7-carboxylate ((6S,7S,9R)-3w)



Yield (54%); 9:1 dr; white solid; m.p. 168-170 °C; $[\alpha]^{30}_D = 83.2$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.27 (m, 4H), 7.22 – 7.18 (m, 2H), 7.11 – 7.04 (m, 1H), 6.22 (s, 1H), 5.92 (ddd, *J* = 17.2, 10.4, 9.2 Hz, 1H), 5.25 (dd, *J* = 10.4, 1.6 Hz, 1H), 5.19 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.14 (s, 1H), 4.03 (t, *J* = 9.2 Hz, 1H), 3.95 (d, *J* = 9.6 Hz, 1H), 3.66 (s, 3H), 3.64 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 173.5, 143.2, 138.5, 137.4, 133.1, 133.0, 129.3, 128.6, 126.5, 124.8, 121.5, 120.8, 120.5, 117.8, 107.9, 67.2, 61.9, 55.8, 51.5, 32.8. HRMS (ESI+) Calcd. For C₂₂H₂₂^{34.9689}ClN₂O₂⁺ ([M+H]⁺): 381.1364, found: 381.1360; C₂₂H₂₂^{36.9659}ClN₂O₂⁺ ([M+H]⁺): 383.1334, found: 383.1333. IR (thin film) ν (cm⁻¹) 3306, 2946, 2854, 1739, 1601, 1451, 1164, 1090, 744. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 11.90 and 14.91 min.


Methyl (6R,7R,9S)-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2H-azepino[3,4,5-cd]indole-7-carboxylate ((6R,7R,9S)-3w)



Yield (55%); 10:1 dr; white solid; m.p. 168-170 °C; $[\alpha]^{30}_D = -86.2$ (*c* 0.50, CH₂Cl₂); HRMS (ESI+) Calcd. For C₂₂H₂₂^{34.9689}ClN₂O₂⁺ ([M+H]⁺): 381.1364, found: 381.1363; C₂₂H₂₂^{36.9659}ClN₂O₂⁺ ([M+H]⁺): 383.1334, found: 383.1332. IR (thin film) ν (cm⁻¹) 3306, 2945, 2854, 1740, 1601, 1451, 1164, 1092, 744. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee


(Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 11.90 and 14.91 min.

Methyl (6*R*,7*S*,9*S*)-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*S*,9*S*)-3w)



Yield (52%); 10:1 dr; white solid; m.p. 166–168 °C; $[\alpha]^{30}_D$ = 83.2 (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.44 – 7.40 (m, 2H), 7.34 – 7.27 (m, 2H), 7.22 – 7.10 (m, 2H), 7.01 (d, *J* = 7.2 Hz, 1H), 6.29 (ddd, *J* = 17.2, 10.0, 8.8 Hz, 1H), 6.21 (s, 1H), 5.11 (dd, *J* = 17.2, 2.0 Hz, 1H), 5.07 (s, 1H), 5.02 (dd, *J* = 10.0, 2.0 Hz, 1H), 4.36 (d, *J* = 8.8 Hz, 1H), 4.22 (d, *J* = 1.8 Hz, 1H), 3.79 (s, 3H), 3.61 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 173.7, 143.6, 139.4, 137.5, 134.2, 133.2, 129.7, 128.5, 126.7, 124.4, 121.6, 120.5, 119.9, 115.2, 107.3, 65.3, 63.2, 54.5, 52.5, 32.7. HRMS (ESI+) Calcd. For C₂₂H₂₂^{34.9689}ClN₂O₂⁺ ([M+H]⁺): 381.1364, found: 381.1364; C₂₂H₂₂^{36.9659}ClN₂O₂⁺ ([M+H]⁺): 383.1334, found: 383.1333. IR (thin film) ν (cm⁻¹) 3305, 2945, 2854, 1740, 1601, 1452, 1164, 1091, 745. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.87 and 6.67 min.


Methyl (6*S*,7*R*,9*R*)-9-(4-chlorophenyl)-2-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*R*,9*R*)-3w)



Yield (56%); 10:1 dr; white solid; m.p. 166–168 °C; $[\alpha]^{30}_D$ = -86.2 (*c* 0.50, CH₂Cl₂); HRMS (ESI+) Calcd. For C₂₂H₂₂^{34.9689}ClN₂O₂⁺ ([M+H]⁺): 381.1364, found: 381.1362; C₂₂H₂₂^{36.9659}ClN₂O₂⁺


([M+H]⁺): 383.1334, found: 383.1334. IR (thin film) ν (cm⁻¹) 3305, 2946, 2854, 1739, 1602, 1452, 1164, 1092, 745. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 11.90 and 14.91 min.

Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-5-fluoro-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3x)




Yield (63%); 14:1 dr; white solid; m.p. 202-204 °C; $[\alpha]^{30}_D = 106.6$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.50 – 7.41 (m, 2H), 7.39 – 7.28 (m, 2H), 7.01 – 6.89 (m, 2H), 6.36 – 6.25 (m, 1H), 6.24 (s, 1H), 5.63 (s, 1H), 5.26 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.11 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.39 (d, *J* = 9.2 Hz, 1H), 3.57 (s, 3H), 3.55 (s, 3H), 1.50 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.5, 154.81 (d, *J* = 234.0 Hz), 145.0, 137.4, 133.16 (d, *J* = 13.8 Hz), 129.9, 128.5, 128.0, 124.2, 120.41 (d, *J* = 16.2 Hz), 118.3, 116.5, 110.3, 110.0, 107.45 (d, *J* = 10.2 Hz), 63.5, 57.6, 51.8, 50.2, 32.8, 29.4. ¹⁹F NMR (376 MHz, CDCl₃) δ -130.0. HRMS (ESI+) Calcd. For C₂₃H₂₃^{34,9689}ClFN₂O₂⁺ ([M+H]⁺): 413.1427, found: 413.1425; C₂₃H₂₃^{36,9659}ClFN₂O₂⁺ ([M+H]⁺): 415.1397, found: 415.1406. IR (thin film) ν (cm⁻¹) 3329, 2920, 2849, 1720, 1583, 1484, 1250, 1132, 783. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.00 and 8.00 min.

Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-6-fluoro-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3y)



Yield (60%); 9:1 dr; white solid; m.p. 122-124 °C; $[\alpha]^{30}_D = 99.8$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.44 – 7.40 (m, 2H), 7.38 – 7.31 (m, 2H), 6.88 (dd, *J* = 8.8, 2.0 Hz, 1H), 6.72 (dd, *J* = 10.4, 2.0 Hz, 1H), 6.35 (s, 1H), 6.34 – 6.24 (m, 1H), 5.68 (s, 1H), 5.21 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.15 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.28 (d, *J* = 9.6 Hz, 1H), 3.94 (s, 3H), 3.61 (s, 3H), 1.42 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.1, 160.29 (d, *J* = 240.0 Hz), 143.1, 137.3, 137.02 (d, *J* = 9.2 Hz), 133.2, 132.50 (d, *J* = 12.8 Hz), 129.4, 128.6, 120.39 (d, *J* = 3.6 Hz), 117.7, 117.4, 108.6, 108.3, 92.69 (d, *J* = 27.2 Hz), 65.6, 64.8, 56.5, 56.3, 51.9, 26.2. ¹⁹F NMR δ -119.5. HRMS (ESI+) Calcd. For C₂₃H₂₃^{34.9689}ClFN₂O₂⁺ ([M+H]⁺): 413.1427, found: 413.1417; C₂₃H₂₃^{36.9659}ClFN₂O₂⁺ ([M+H]⁺): 415.1397, found: 415.1399. IR (thin film) ν (cm⁻¹) 3341, 2931, 2854, 1733, 1618, 1489, 1237, 1093, 770. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.93 and 8.56 min.


Methyl (6S,7S,9R)-9-(4-chlorophenyl)-7-fluoro-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2H-azepino[3,4,5-cd]indole-7-carboxylate ((6S,7S,9R)-3z)



Yield (54%); 11:1 dr; white solid; m.p. 104-106 °C; $[\alpha]^{30}_D = 91.8$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.44 – 7.39 (m, 2H), 7.37 – 7.31 (m, 2H), 6.81 – 6.77 (m, 1H), 6.77 – 6.75 (m, 1H), 6.36 – 6.25 (m, 1H), 6.08 (s, 1H), 5.77 (s, 1H), 5.17 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.12 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.32 (d, *J* = 9.6 Hz, 1H), 3.79 (s, 3H), 3.60 (s, 3H), 1.41 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.3, 149.0 (d, *J* = 242.4 Hz), 143.6, 137.9, 133.0, 130.4, 130.3, 129.4, 128.6, 127.6, 124.7 (d, *J* =


10.4 Hz), 121.0, 118.9 (d, J = 6.4 Hz), 116.8, 107.3 (d, J = 17.9 Hz), 65.0, 56.1, 55.8, 51.8, 35.5, 35.4. ^{19}F NMR (376 MHz, CDCl_3) δ -119.5. HRMS (ESI+) Calcd. For $\text{C}_{23}\text{H}_{23}^{34.9689}\text{ClFN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 413.1427, found: 413.1421; $\text{C}_{23}\text{H}_{23}^{36.9659}\text{ClFN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 415.1397, found: 415.1407. IR (thin film) ν (cm^{-1}) 3357, 2949, 2854, 1735, 1591, 1485, 1240, 1083, 753. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.05 and 5.46 min.

Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-4-bromo-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3A)




Yield (63%); 12:1 dr; white solid; m.p. 176-178 °C; $[\alpha]^{30}\text{D} = 48.0$ (c 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.44 – 7.40 (m, 2H), 7.35 – 7.30 (m, 2H), 7.24 – 7.22 (m, 1H), 7.07 – 7.04 (m, 1H), 6.36 – 7.24 (m, 1H), 6.14 (s, 1H), 5.71 (s, 1H), 5.20 (dd, J = 17.2 Hz, 1.6 Hz, 1H), 5.12 (dd, J = 10.4, 1.6 Hz, 1H), 4.21 (d, J = 9.6 Hz, 1H), 3.58 (s, 3H), 3.55 (s, 3H), 1.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.2, 143.9, 137.8, 137.7, 136.7, 133.1, 129.5, 128.6, 126.6, 123.6, 122.2, 119.9, 117.0, 115.5, 110.2, 64.5, 56.7, 56.2, 51.8, 32.7, 27.0. HRMS (ESI+) Calcd. For $\text{C}_{23}\text{H}_{23}^{34.9689}\text{Cl}^{78.9183}\text{BrN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 473.0626, found: 473.0630; $\text{C}_{23}\text{H}_{23}^{36.9659}\text{Cl}^{78.9183}\text{BrN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 475.0596, found: 475.0601; $\text{C}_{23}\text{H}_{23}^{36.9659}\text{Cl}^{80.9163}\text{BrN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 477.0576, found: 477.0570. IR (thin film) ν (cm^{-1}) 3354, 2921, 2851, 1731, 1632, 1487, 1239, 1039, 788. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.21 and 7.40 min.

Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-2,7-dimethyl-4-phenyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3B)



Yield (56%); 20:1 dr; white solid; m.p. 186-188 °C; $[\alpha]^{30}_{\text{D}} = 29.8$ (c 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.69 – 7.64 (m, 2H), 7.49 – 7.41 (m, 4H), 7.37 – 7.30 (m, 3H), 7.29 – 7.27 (m, 1H), 7.26 – 7.23 (m, 1H), 7.21 (s, 1H), 6.46 – 6.35 (m, 1H), 6.20 (s, 1H), 5.81 (s, 1H), 5.23 (dd, $J = 17.2, 1.2$ Hz, 1H), 5.12 (dd, $J = 10.4, 1.2$ Hz, 1H), 4.37 (d, $J = 9.6$ Hz, 1H), 3.64 (s, 3H), 3.60 (s, 3H), 1.48 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.5, 144.2, 142.5, 138.4, 137.5, 135.6, 135.1, 132.9, 129.6, 128.6, 128.5, 127.4, 126.67, 126.5, 124.2, 119.7, 119.1, 116.6, 105.8, 64.8, 57.2, 56.6, 51.8, 32.78, 27.0. HRMS (ESI+) Calcd. For $\text{C}_{29}\text{H}_{28}^{34.9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 471.1834, found: 471.1827; $\text{C}_{29}\text{H}_{28}^{36.9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 473.1804, found: 473.1806. IR (thin film) ν (cm^{-1}) 3341, 2927, 2854, 1730, 1597, 1486, 1238, 1091, 763. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak ID, *i*-propanol /hexane = 5/95, flow rate 1.0 mL/min, $\lambda = 230$ nm); $t_r = 7.93$ and 10.55 min.


Methyl (6S,7S,9R)-9-(4-chlorophenyl)-2,7-dimethyl-4,6-divinyl-6,7,8,9-tetrahydro-2H-azepino[3,4,5-cd]indole-7-carboxylate ((6S,7S,9R)-3C)



Yield (64%); 18:1 dr; white solid; m.p. 186-188 °C; $[\alpha]^{30}_{\text{D}} = 29.0$ (c 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.46 – 7.40 (m, 2H), 7.35 – 7.30 (m, 2H), 7.08 (d, $J = 11.2$ Hz, 2H), 6.81 (dd, $J = 17.2, 10.8$ Hz, 1H), 6.42 – 6.30 (m, 1H), 6.16 (s, 1H), 5.80 – 5.72 (m, 1H), 5.76 (s, 1H), 5.24 – 5.14 (m, 2H), 5.11 (dd, $J = 10.4, 1.6$ Hz, 1H), 4.29 (d, $J = 9.6$ Hz, 1H), 3.59 (s, 3H), 3.58 (s, 3H), 1.44 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.5, 144.2, 138.3, 137.9, 137.2, 134.8, 132.9, 131.9, 129.5, 128.5, 126.8,


124.8, 119.8, 117.6, 116.6, 111.7, 105.4, 64.7, 57.0, 56.4, 51.8, 32.7, 26.9. HRMS (ESI+) Calcd. For $C_{25}H_{26}^{34.9689}ClN_2O_2^+$ ($[M+H]^+$): 421.1677, found: 421.1679; $C_{25}H_{26}^{36.9659}ClN_2O_2^+$ ($[M+H]^+$): 423.1647, found: 423.1651. IR (thin film) ν (cm⁻¹) 3330, 2974, 2925, 1722, 1625, 1485, 1249, 1133, 782. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak IC, *i*-propanol /hexane = 5/95, flow rate 1.0 mL/min, λ = 280 nm); t_r = 8.07 and 10.42 min.

Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-4-cyclopropyl-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3D)




Yield (61%); 13:1 dr; white solid; m.p. 166–168 °C; $[\alpha]^{30}_D = 66.0$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.45 – 7.39 (m, 2H), 7.35 – 7.29 (m, 2H), 6.74 (d, *J* = 10.4 Hz, 2H), 6.04 – 6.28 (m, 1H), 6.07 (s, 1H), 5.74 (s, 1H), 5.23 – 5.16 (m, 1H), 5.13 – 5.07 (m, 1H), 4.27 (d, *J* = 9.6 Hz, 1H), 3.58 (s, 3H), 3.54 (s, 3H), 2.06 – 1.97 (m, 1H), 1.42 (s, 3H), 0.98 – 0.91 (m, 2H), 0.77 – 0.67 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 175.4, 144.2, 138.4, 138.0, 137.3, 134.4, 132.8, 129.5, 128.4, 125.4, 123.2, 119.7, 118.1, 116.4, 103.7, 64.8, 56.5, 51.7, 32.5, 26.7, 15.9, 9.1, 9.0. HRMS (ESI+) Calcd. For $C_{26}H_{28}^{34.9689}ClN_2O_2^+$ ($[M+H]^+$): 435.1834, found: 435.1832; $C_{26}H_{28}^{36.9659}ClN_2O_2^+$ ($[M+H]^+$): 437.1804, found: 437.1810. IR (thin film) ν (cm⁻¹) 3340, 2930, 2857, 1731, 1617, 1488, 1239, 1093, 779. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak IC, *i*-propanol /hexane = 5/95, flow rate 1.0 mL/min, λ = 230 nm); t_r = 8.10 and 10.74 min.

Methyl (6*S*,7*S*,9*R*)-2-allyl-9-(4-chlorophenyl)-7-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3E)



Yield (63%); 10:1 dr; white solid; m.p. 118-120 °C; $[\alpha]^{30}_{\text{D}} = 67.2$ (*c* 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.46 – 7.40 (m, 2H), 7.36 – 7.29 (m, 2H), 7.18 – 7.07 (m, 2H), 6.93 (d, *J* = 6.4 Hz, 1H), 6.40 – 6.30 (m, 1H), 6.19 (s, 1H), 5.94 – 5.83 (m, 1H), 5.81 (s, 1H), 5.20 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.14 (dd, *J* = 10.4, 1.6 Hz, 1H), 5.11 (dd, *J* = 10.4, 1.6 Hz, 1H), 5.03 (dd, *J* = 17.2, 1.6 Hz, 1H), 4.60 – 4.46 (m, 2H), 4.40 (d, *J* = 9.6 Hz, 1H), 3.59 (s, 3H), 1.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.4, 143.8, 138.0, 136.4, 134.8, 133.3, 132.9, 129.5, 128.5, 125.4, 124.8, 122.1, 120.8, 118.9, 117.3, 116.7, 107.6, 65.2, 56.2, 51.7, 48.8, 29.7, 25.9. HRMS (ESI $^+$) Calcd. For $\text{C}_{25}\text{H}_{26}^{34.9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 421.1677, found: 421.1673; $\text{C}_{25}\text{H}_{26}^{36.9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 423.1647, found: 423.1659. IR (thin film) ν (cm^{-1}) 3336, 2924, 2853, 1730, 1600, 1487, 1240, 1092, 747. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.13 and 6.60 min.


Methyl (6S,7S,9R)-2-benzyl-9-(4-chlorophenyl)-7-methyl-6-vinyl-6,7,8,9-tetrahydro-2H-azepino[3,4,5-cd]indole-7-carboxylate ((6S,7S,9R)-3F)



Yield (61%); 15:1 dr; white solid; m.p. 88°C-90 °C; $[\alpha]^{30}_{\text{D}} = 70.8$ (*c* 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.45 – 7.40 (m, 2H), 7.35 – 7.30 (m, 2H), 7.25 – 7.20 (m, 3H), 7.12 – 7.05 (m, 2H), 7.04 – 7.00 (m, 2H), 6.93 (d, *J* = 6.8 Hz, 1H), 6.42 – 6.30 (m, 1H), 6.25 (s, 1H), 5.84 (s, 1H), 5.25 – 5.19 (m, 1H), 5.19 – 5.11 (m, 2H), 5.11 – 5.04 (m, 1H), 4.43 (d, *J* = 9.6 Hz, 1H), 3.60 (s, 3H), 1.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.4, 143.7, 137.8, 137.4, 136.7, 134.8, 132.9, 129.4, 128.5,


128.5, 127.5 126.6, 125.6, 125.2, 122.3, 121.2, 119.0, 116.8, 107.8, 65.3, 56.2, 51.7, 50.0, 29.4, 25.7. HRMS (ESI+) Calcd. For $C_{29}H_{28}^{34.9689}ClN_2O_2^+$ ($[M+H]^+$): 471.1834, found: 471.1837; $C_{29}H_{28}^{36.9659}ClN_2O_2^+$ ($[M+H]^+$): 473.1804, found: 473.1814. IR (thin film) ν (cm^{-1}) 3339, 2928, 2869, 1731, 1600, 1488, 1240, 1091, 740. The product was analyzed by HPLC to determine the enantiomeric excess: 99% ee (Chiralpak IC, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.65 and 8.32 min.

Methyl (6*S*,7*S*,9*R*)-9-(4-chlorophenyl)-7-methyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*S*,9*R*)-3G)




Yield (66%); 11:1 dr; white solid; m.p. 158–160 °C; $[\alpha]^{30}_D = 40.6$ (c 0.50, CH_2Cl_2); 1H NMR (400 MHz, $CDCl_3$) δ 8.03 (s, 1H), 7.56 – 7.50 (m, 2H), 7.38 – 7.32 (m, 2H), 7.19 – 7.07 (m, 2H), 6.92 (d, J = 7.2 Hz, 1H), 6.33 (ddd, J = 17.2, 10.4, 7.6 Hz, 1H), 6.15 (s, 1H), 5.45 (s, 1H), 5.37 – 5.23 (m, 1H), 5.19 – 5.03 (m, 1H), 4.08 (d, J = 7.6 Hz, 1H), 3.77 – 3.72 (m, 1H), 3.37 (s, 3H), 1.53 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 176.8, 142.9, 137.7, 136.4, 133.5, 133.0, 129.8, 128.6, 125.2, 122.4, 121.6, 121.1, 120.3, 118.5, 109.5, 66.3, 57.9, 56.1, 51.8, 23.6. HRMS (ESI+) Calcd. For $C_{22}H_{22}^{34.9689}ClN_2O_2^+$ ($[M+H]^+$): 381.1364, found: 381.1363; $C_{22}H_{22}^{36.9659}ClN_2O_2^+$ ($[M+H]^+$): 383.1334, found: 383.1343. IR (thin film) ν (cm^{-1}) 3396, 2926, 2852, 1726, 1619, 1487, 1240, 1092, 749. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 11.90 and 14.91 min.

4. Scale-Up Experiment and Synthetic Transformation




Scheme S1 Scale-Up Experiment and Synthetic Transformation



A flame dried Schlenk tube **A** was cooled to room temperature and filled with N₂. To this flask were added [Ir(COD)Cl]₂ (0.05 mmol), (R,R,R)-**L5** (0.10 mmol), degassed THF (4 mL) and degassed *n*-propylamine (1 mL). The reaction mixture was heated at 50 °C for 30 min and then the volatile solvents were removed under vacuum to gain a pale-yellow solid. Meanwhile, Cu(MeCN)₄BF₄ (0.10 mmol) and (*S,S_p*)-*i*Pr-Phosferrox-**L1** (0.11 mmol) were dissolved in 15.0 mL of DCE in a Schlenk tube **B**, and stirred at room temperature for about 40 min. Then, aldimine ester **1** (2.4 mmol), 4-indolyl allylic carbonate **2** (2.0 mmol) and K₂CO₃ (4.0 mmol) were added into the Schlenk tube **A** and filled with N₂. The Cu/**L1** complex solution was then transferred from the Schlenk tube **B** to the Schlenk


tube A via syringe. Finally, the reaction mixture was continuously stirred at room temperature under N₂ atmosphere. Once starting material was consumed (monitored by TLC), the residue was separated by flash column chromatography to give the crude product. The crude product was dissolved in dichloromethane and two equivalent of *para*-chlorobenzaldehyde and Zn(OTf)₂ (50 mol%) were added. Once starting material was consumed (monitored by TLC), the reaction was quenched with 1 mol of HCl solution (5 mL). The layers were separated, and the aqueous layer was extracted with DCM (5 mL x 3). The combined organic components were washed with saturated brine (10 mL), dried over anhydrous Na₂SO₄, filtration and evaporated in vacuum. After evaporation of the solvent under vacuum, the crude mixture was flushed with short silica gel plug to remove the metal complex and the diastereoselectivity was determined with ¹H NMR analysis. Then, the whole residue was further purified by column chromatography to give the desired product, which was then directly analyzed by HPLC to determine the enantiomeric excess.



Fresh prepared diazomethane solution (0.5 M in Et₂O, 2 mL) and (6*R*,7*S*,9*S*)-3*a* (78.8 mg, 0.2 mmol) were added into a Schlenk tube. Under a positive nitrogen pressure, the reaction was cooled to -20 °C, and Pd(OAc)₂ (1.5 mg, 1 mol %) was added in one portion with gas evolution. After stirring for 1 hour in -20 °C, the reaction was moved to room temperature and stirred overnight. While the reaction was partly completed, the solvent was removed under reduced pressure and the residue was purified by a flash column chromatography (PE/EA = 6/1) to afford the product (6*R*,7*S*,9*S*)-4.

Methyl (6*R*,7*S*,9*S*)-9-(4-chlorophenyl)-6-cyclopropyl-2,7-dimethyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*S*,9*S*)-4): Yield (77%); >20:1 dr; white solid; m.p. 180-182 °C; [α]³⁰_D = -53.0 (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.52 – 7.46 (m, 2H), 7.36


– 7.30 (m, 2H), 7.21 – 7.11 (m, 2H), 6.89 (dd, J = 5.6, 2.4 Hz, 1H), 6.22 (s, 1H), 5.31 (s, 1H), 3.78 (s, 3H), 3.63 (s, 3H), 2.74 (d, J = 9.6 Hz, 1H), 1.75 – 1.65 (m, 1H), 1.58 (s, 3H), 0.57 – 0.44 (m, 1H), 0.36 – 0.28 (m, 2H), 0.26 – 0.16 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 177.6, 144.6, 136.8, 135.0, 133.0, 130.0, 128.5, 126.4, 124.6, 121.4, 120.6, 119.9, 107.4, 64.1, 59.3, 56.2, 52.2, 32.7, 21.6, 15.9, 6.1, 3.8. HRMS (ESI+) Calcd. For $\text{C}_{24}\text{H}_{26}^{34.9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 409.1677, found: 409.1667; $\text{C}_{24}\text{H}_{26}^{36.9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 411.1647, found: 411.1653. IR (thin film) ν (cm^{-1}) 3340, 2946, 2856, 1730, 1599, 1455, 1245, 1089, 748. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak IE, *i*-propanol /hexane = 5/95, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.22 and 6.87 min.



To a solution of $[\text{Ir}(\text{COD})\text{Cl}]_2$ (4.0 mg, 3 mol %) and bis(diphenylphosphino)methane (DPPM, 4.6 mg, 6 mol %) in anhydrous DCM (2 mL) was added $(6R,7S,9S)\text{-3a}$ (78.8 g, 0.2 mmol) in one portion under a positive argon pressure. Then 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (HBpin, 58 μL , 0.4 mmol) was added at room temperature and the resulting solution was stirred overnight. The reaction mixture was quenched with MeOH (1 mL) and concentrated under reduced pressure. The residue was purified by silica-gel flash column chromatography (PE/EA = 3/1, with 1% MeOH) to afford the product $(6R,7S,9S)\text{-5}$.

Methyl $(6R,7S,9S)$ -9-(4-chlorophenyl)-2,7-dimethyl-6-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((*6R,7S,9S*)-5): Yield (89%); >20:1 dr; white solid; m.p. 114–116 °C; $[\alpha]^{30}_D = -52.0$ (c 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.52 – 7.47 (m, 2H), 7.34 – 7.30 (m, 2H), 7.16 – 7.07 (m, 2H), 6.96 – 6.90 (m, 1H), 6.18 (s, 1H), 5.28 (s, 1H), 3.80 (s, 3H), 3.61 (s, 3H), 3.36 (dd, J = 9.6, 3.2 Hz, 1H), 2.08 – 1.83 (m, 1H), 1.65

– 1.60 (m, 1H), 1.55 (s, 3H), 1.20 (d, J = 2.4 Hz, 12H), 0.71 – 0.62 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 177.9, 144.6, 137.1, 134.1, 132.9, 130.1, 128.4, 126.3, 124.6, 121.7, 120.9, 119.7, 107.3, 82.7, 64.6, 56.6, 56.3, 52.8, 32.6, 29.4, 28.3, 24.8, 21.7. HRMS (ESI $^+$) Calcd. For $\text{C}_{29}\text{H}_{37}\text{B}^{34.9689}\text{ClN}_2\text{O}_4^+$ ($[\text{M}+\text{H}]^+$): 523.2529, found: 523.2534; $\text{C}_{29}\text{H}_{37}\text{B}^{36.9659}\text{ClN}_2\text{O}_4^+$ ($[\text{M}+\text{H}]^+$): 525.2499, found: 525.2502. IR (thin film) ν (cm^{-1}) 3373, 2978, 2935, 1728, 1583, 1454, 1374, 1244, 1146, 1091, 751. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.26 and 6.09 min.




Under nitrogen atmosphere, to a solution of $(6R,7S,9S)\text{-3a}$ (78.8 mg, 0.2 mmol) in anhydrous THF (2 mL) was added NaBH_4 (1.0 mmol), the reaction was then moved into room temperature and continuously stirred until 3a complete consumption of starting material (detected by TLC). The reaction mixture was quenched with H_2O , extracted with EA ($\times 3$) and filtered through celite to remove the colloid. The organic layer was combined, washed with brine, dried over Na_2SO_4 before evaporation. Then the residue was purified by a flash column chromatography (EA/PE=1:2) to afford the product $(6R,7S,9S)\text{-6}$.

Methyl $(6R,7S,9S)$ -9-(4-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino

[3,4,5-*cd*]indol-7-yl)methanol (($6R,7S,9S\text{-6}$): Yield (75%); $>20:1$ dr; white solid; m.p. 82–84 °C; $[\alpha]^{30}_D = -54.2$ (c 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.40 – 7.36 (m, 2H), 7.35 – 7.30 (m, 2H), 7.21 – 7.11 (m, 2H), 6.91 (dd, J = 6.0, 2.0 Hz, 1H), 6.26 (s, 1H), 6.17 (ddd, J = 17.2, 10.4, 8.4 Hz, 1H), 5.19 (s, 1H), 5.06 (dd, J = 10.4, 1.6 Hz, 1H), 4.94 (dd, J = 17.2, 1.6 Hz, 1H), 3.67 (d, J = 8.4 Hz, 1H), 3.64 (s, 3H), 3.53 (d, J = 10.4 Hz, 1H), 3.37 (d, J = 10.4 Hz, 1H), 1.38 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 144.2, 139.3, 136.9, 134.2, 133.0, 129.7, 128.6, 126.5, 125.7, 121.9, 120.9, 120.1,

116.9, 107.3, 69.7, 59.3, 58.4, 56.7, 32.7, 19.7. HRMS (ESI⁺) Calcd. For C₂₂H₂₄^{34,9689}ClN₂O⁺ ([M+H]⁺): 367.1572, found: 367.1568; C₂₂H₂₄^{36,9659}ClN₂O⁺ ([M+H]⁺): 369.1542, found: 369.1550. IR (thin film) ν (cm⁻¹) 3700, 3369, 2923, 2851, 1728, 1581, 1457, 1375, 1086, 751. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol /hexane = 20/80, flow rate 1.0 mL/min, λ = 230 nm); t_r = 5.30 and 6.35 min.

5. TFA-Promoted C9-Epimerization of 6,9-cis-3a to Access Another Four Stereoisomers 6,9-trans-3a




Scheme S2. TFA-Promoted C9-Epimerization of 6,9-cis-3a to Access Another Four Stereoisomers 6,9-trans-3a

General Reaction Procedure A for (6S,7S,9R)-3a and (6R,7R,9S)-3a: Under air atmosphere, to a solution of (6S,7S,9R)-3a or (6R,7R,9S)-3a (78.8 mg, 0.2 mmol) in DCM (2 mL) was added TFA (0.4 mmol), the reaction was continuously stirred until complete consumption of starting material (detected by TLC). The reaction mixture was quenched with NaHCO₃ (aq), extracted with DCM (\times 3). The

organic layer was combined, washed with brine, dried over Na_2SO_4 before evaporation. Then the residue was purified by a column chromatography to afford the product (*6S,7S,9S*)-**3a** or (*6R,7R,9R*)-**3a**.

General Reaction Procedure B for (*6R,7S,9S*)-**3a** and (*6S,7R,9R*)-**3a**: under air atmosphere, to a solution of (*6R,7S,9S*)-**3a** or (*6S,7R,9R*)-**3a** (78.8 mg, 0.2 mmol) in DCM (2 mL) was added TFA (1.0 mmol), the reaction was continuously stirred until complete consumption of starting material (detected by TLC). The reaction mixture was quenched with NaHCO_3 (aq), extracted with DCM (\times 3). The organic layer was combined, washed with brine, dried over Na_2SO_4 before evaporation. Then the residue was purified by a column chromatography to afford the product (*6R,7S,9R*)-**3a** or (*6S,7R,9S*)-**3a** with the starting material being recovered.


Methyl (*6S,7S,9S*)-9-(4-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((*6S,7S,9S*)-3a**)**



Following **General Reaction Procedure A**: Yield (95%); >20:1 dr; white solid; m.p. 138–140 °C; $[\alpha]^{30}_{\text{D}} = 62.2$ (*c* 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.54 (d, *J* = 8.4 Hz, 2H), 7.36 (d, *J* = 8.4 Hz, 2H), 7.18 – 7.08 (m, 2H), 6.95 – 6.89 (m, 1H), 6.32 (ddd, *J* = 17.2, 10.4, 7.8 Hz, 1H), 6.04 (s, 1H), 5.45 (s, 1H), 5.29 (dd, *J* = 17.2, 1.6, 1H), 5.09 (dd, *J* = 10.4, 1.6, 1H), 4.08 (d, *J* = 7.6 Hz, 1H), 3.61 (s, 3H), 3.37 (s, 3H), 1.53 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 176.8, 143.1, 137.7, 137.2, 133.6, 133.0, 129.8, 128.7, 125.9, 125.5, 121.9, 120.1, 119.8, 118.5, 107.6, 66.3, 57.9, 56.1, 51.7, 32.7, 23.4. HRMS (ESI+) Calcd. For $\text{C}_{23}\text{H}_{24}^{34.9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 395.1521, found: 395.1511; $\text{C}_{23}\text{H}_{24}^{36.9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 397.1491, found: 397.1497. IR (thin film) ν (cm^{-1}) 3337, 3049, 2947, 1730, 1597, 1487, 1246, 1088, 748. The product was analyzed by HPLC to determine the


enantiomeric excess: >99% ee (Chiralpak IE, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.62 and 7.30 min.

Methyl (6*R*,7*R*,9*R*)-9-(4-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*R*,9*R*)-3a)



Following **General Reaction Procedure A**: Yield (91%); >20:1 dr; white solid; m.p. 138-140 °C; $[\alpha]^{30}_{\text{D}} = -60.7$ (*c* 0.50, CH_2Cl_2); HRMS (ESI+) Calcd. For $\text{C}_{23}\text{H}_{24}^{34,9689}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 395.1521, found: 395.1520; $\text{C}_{23}\text{H}_{24}^{36,9659}\text{ClN}_2\text{O}_2^+$ ($[\text{M}+\text{H}]^+$): 397.1491, found: 397.1497. IR (thin film) ν (cm^{-1}) 3333, 3068, 2929, 1728, 1577, 1486, 1245, 1090, 745. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak IE, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.62 and 7.30 min.


Methyl (6*R*,7*S*,9*R*)-9-(4-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*R*,7*S*,9*R*)-3a)



Following **General Reaction Procedure B**: Yield (93% BRSM); >20:1 dr; white solid; m.p. 130-132 °C; $[\alpha]^{30}_{\text{D}} = -96.8$ (*c* 0.50, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.43 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.22 – 7.15 (m, 2H), 6.98-6.92 (m, 1H), 6.26 (ddd, J = 17.2, 10.4, 7.2 Hz, 1H), 6.06 (s, 1H), 5.65 (s, 1H), 5.04 (dd, J = 10.4, 1.6 Hz, 1H), 4.83 (dd, J = 17.2, 1.6 Hz, 1H), 3.99 (d, J = 7.2 Hz, 1H), 3.75 (s, 3H), 3.63 (s, 3H), 1.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 176.4, 142.6, 140.0, 137.3, 132.7, 132.2, 129.2, 128.5, 126.3, 125.6, 122.4, 121.6, 120.6, 116.8, 108.3, 67.6, 58.4,

55.5, 52.2 32.7, 28.4. HRMS (ESI+) Calcd. For $C_{23}H_{24}^{34.9689}ClN_2O_2^+$ ($[M+H]^+$): 395.1521, found: 395.1518; $C_{23}H_{24}^{36.9659}ClN_2O_2^+$ ($[M+H]^+$): 397.1491, found: 397.1495. IR (thin film) ν (cm⁻¹) 3343, 3047, 2929, 1727, 1576, 1486, 1246, 1089, 745. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 7.91 and 8.90 min.

Methyl (6*S*,7*R*,9*S*)-9-(4-chlorophenyl)-2,7-dimethyl-6-vinyl-6,7,8,9-tetrahydro-2*H*-azepino[3,4,5-*cd*]indole-7-carboxylate ((6*S*,7*R*,9*S*)-3a)



Following **General Reaction Procedure B:** Yield (95% BRSM); >20:1 dr; white solid; m.p. 130-132 °C; $[\alpha]^{30}_D = 93.0$ (*c* 0.50, CH₂Cl₂); HRMS (ESI+) Calcd. For $C_{23}H_{24}^{34.9689}ClN_2O_2^+$ ($[M+H]^+$): 395.1521, found: 395.1517; $C_{23}H_{24}^{36.9659}ClN_2O_2^+$ ($[M+H]^+$): 397.1491, found: 397.1494. IR (thin film) ν (cm⁻¹) 3340, 3063, 2944, 1729, 1593, 1483, 1241, 1082, 751. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiraldak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 230 nm); t_r = 6.62 and 7.30 min.

6. One-pot allylation/cyclization/epimerization with TFA as the cyclization promoter



A flame dried Schlenk tube **A** was cooled to room temperature and filled with N₂. To this flask were added [Ir(COD)Cl]₂ (0.005 mmol), (S,S,S)-**L5** (0.010 mmol), degassed THF (0.5 mL) and degassed *n*-propylamine (0.5 mL). The reaction mixture was heated at 50 °C for 30 min and then the volatile solvents were removed under vacuum to gain a pale-yellow solid. Meanwhile, Cu(MeCN)₄BF₄ (0.01 mmol) and (S,*S*_p)-*i*Pr-Phosferrox-**L1** (0.011 mmol) were dissolved in 1.0 mL of DCE in a Schlenk tube **B**, and stirred at room temperature for about 40 min. Then, aldimine ester **1a** (0.30 mmol), 4-indolyl allylic carbonate **2a** (0.20 mmol) and K₂CO₃ (0.40 mmol) were added into the Schlenk tube **A** and filled with N₂. The Cu/**L1** complex solution was then transferred from the Schlenk tube **B** to the Schlenk tube **A** *via* syringe. Finally, the reaction mixture was continuously stirred at room temperature under N₂ atmosphere. Once 4-indolyl allylic carbonate was consumed (monitored by TLC), two equivalents of the *p*-ClC₆H₄CHO and TFA (200 mol%) were added. When the generated allylation intermediate in first step was consumed (monitored by TLC), the reaction was quenched with saturated NaHCO₃ solution. The layers were separated, and the aqueous layer was extracted with DCM (5 mL x 3). The combined organic components were washed with saturated brine (5 mL), dried over anhydrous Na₂SO₄, filtration and evaporated in vacuum. After evaporation of the solvent under vacuum, the crude mixture was flushed with short silica gel plug to remove the metal complex and the diastereoselectivity was determined with ¹H NMR analysis. Then, the whole residue was further purified by column chromatography to give the desired product, which was then directly analyzed by HPLC to determine the enantiomeric excess.

7. References

1. C.-J. Wang, G. Liang, Z.-Y. Xue, F. Gao, *J. Am. Chem. Soc.* 2008, **130**, 17250-17251.
2. (a) M. A. Blanchette, W. Choy, J. T. Davis, A. P. Essenfeld, S. Masamune, W. R. Roush, T. Sakai, *Tetrahedron Lett.* 1984, **25**, 2183-2186. (b) J.-Q. Li, B. Peters, P. G. Andersson, *Chem. - Eur. J.* 2011, **17**, 11143-11145. (c) D. J. Weix, D. Marković, M. Ueda, J. F. Hartwig, *Org. Lett.* 2009, **11**, 2944-2947.
3. C. J. Richards, A. W. Mulvaney, *Tetrahedron: Asymmetry* 1996, **7**, 1419-1430.
4. W.-B. Liu, C. Zheng, C.-X. Zhuo, L.-X. Dai, S.-L. You, *J. Am. Chem. Soc.* 2012, **134**, 4812-4821.
5. C. R. Smith, D. J. Mans, T. V. Rajanbabu, *Org. Synth.* 2012, **85**, 238-247.
6. M. d'Augustin, L. Palais, A. Alexakis, *Angew. Chem. Int. Ed.* 2005, **44**, 1376-1378.
7. (a) C. Tresse, C. Guissart, S. Schweizer, Y. Bouhoute, A.-C. Chany, M.-L. Goddard, N. Blanchard, G. Evano, *Adv. Synth. Catal.* 2014, **356**, 2051-2060. (b) B. Bartels, C. García-Yebra, F. Rominger, G. Helmchen, *Eur. J. Inorg. Chem.* 2002, **2002**, 2569-2586.

8. X-ray Structures of (6S,7S,9R)-3a, (6R,7R,9R)-3a, and (6R,7S,9R)-3a




Figure S1. X-ray structure of (6S,7S,9R)-3a

Crystal data for (6S,7S,9R)-3a: $\text{C}_{23}\text{H}_{23}\text{ClN}_2\text{O}_2$, $M_r = 394.88$, $T = 296$ K, monoclinic, space group $P12_1I$, $a = 9.606(10)$, $b = 7.933(10)$, $c = 13.748(10)$ Å, $\beta = 101.1060(10)$ °, $V = 1028.1(19)$ Å³, $Z = 2$, 8054 unique reflections, final $R_1 = 0.0431$ and $wR_2 = 0.1141$ for 8320 observed [$I > 2\sigma(I)$] reflections, Flack $\chi = -0.012(8)$. CCDC 2090369 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).




Figure S2. X-ray structure of (6R,7R,9R)-3a

Crystal data for (6R,7R,9R)-3a: $\text{C}_{23}\text{H}_{23}\text{ClN}_2\text{O}_2$, $M_r = 394.88$, $T = 296$ K, orthorhombic, space group $P2_12_12_1$, $a = 9.119(5)$, $b = 17.378(10)$, $c = 50.209(3)$ Å, $V = 7956.7(8)$ Å³, $Z = 16$, 3930 unique reflections, final $R_1 = 0.0342$ and $wR_2 = 0.0902$ for 4034 observed [$I > 2\sigma(I)$] reflections, Flack $\chi = 0.013(3)$. CCDC 2090370 contains the supplementary crystallographic data for this paper. These data

can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).






Figure S3. X-ray structure of (6*R*,7*S*,9*R*)-3a


Crystal data for (6*R*,7*S*,9*R*)-3a: C₂₃H₂₃ClN₂O₂, M_r = 394.88, T = 296 K, orthorhombic, space group *P*2₁2₁2₁, *a* = 9.299(10), *b* = 18.085(2), *c* = 24.744(2) Å, V = 4161.3(7) Å³, Z = 4, 8054 unique reflections, final *R*₁ = 0.0431 and *wR*₂ = 0.1141 for 8320 observed [*I*>2σ(*I*)] reflections, Flack χ = -0.004(6). CCDC 2090371 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).

9. NMR and HPLC Spectra


¹H NMR (400 MHz) of (*E*)-**2a** in CDCl₃




¹H NMR (400 MHz) of (Z)-2a' in CDCl₃




¹³C NMR (400 MHz) of (Z)-2a' in CDCl₃




¹H NMR (400 MHz) of **2x** in CDCl₃




¹³C NMR (101 MHz) of **2x** in CDCl₃




¹⁹F NMR (376 MHz) of **2x** in CDCl₃




¹H NMR (400 MHz) of **2y** in CDCl₃




^{13}C NMR (101 MHz) of **2y** in CDCl_3




^{19}F NMR (376 MHz) of **2y** in CDCl_3




¹H NMR (400 MHz) of **2z** in CDCl₃




¹³C NMR (101 MHz) of **2z** in CDCl₃




¹⁹F NMR (376 MHz) of **2z** in CDCl₃




¹H NMR (400 MHz) of **2A** in CDCl₃




¹³C NMR (101 MHz) of **2A** in CDCl₃




¹H NMR (400 MHz) of **2B** in CDCl₃




^{13}C NMR (101 MHz) of **2B** in CDCl_3




^1H NMR (400 MHz) of **2C** in CDCl_3




^{13}C NMR (101 MHz) of **2C** in CDCl_3




^1H NMR (400 MHz) of **2D** in CDCl_3




¹³C NMR (101 MHz) of **2D** in CDCl₃




¹H NMR (400 MHz) of **2E** in CDCl₃




¹³C NMR (101 MHz) of **2E** in CDCl₃




¹H NMR (400 MHz) of **2F** in CDCl₃




^{13}C NMR (101 MHz) of **2F** in CDCl_3




^1H NMR (400 MHz) of **2G** in CDCl_3




¹³C NMR (101 MHz) of **2G** in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-**3a** in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-3a in CDCl₃




¹H NMR (400 MHz) of (6*R*,7*S*,9*S*)-3a in CDCl₃




¹³C NMR (101 MHz) of (*6R,7S,9S*)-**3a** in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*S*)-3a in CDCl₃




¹H NMR (400 MHz) of (6*R*,7*S*,9*R*)-3a in CDCl₃




¹³C NMR (101 MHz) of (*6R,7S,9R*)-**3a** in CDCl₃




¹H NMR (400 MHz) of (*6S,7S,9R*)-**3b** in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-**3b** in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3c in CDCl₃




^{13}C NMR (101 MHz) of (*6S,7S,9R*)-**3c** in CDCl_3




^{19}F NMR (376 MHz) of (*6S,7S,9R*)-**3c** in CDCl_3





¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3d in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-3d in CDCl₃







¹H NMR (400 MHz) of (*6S,7S,9R*)-**3f** in CDCl₃




¹³C NMR (101 MHz) of (*6S,7S,9R*)-**3f** in CDCl₃







^1H NMR (400 MHz) of (*6S,7S,9R*)-**3g** in CDCl_3




^{13}C NMR (101 MHz) of (*6S,7S,9R*)-**3g** in CDCl_3









¹H NMR (400 MHz) of (*6S,7S,9R*)-**3j** in CDCl₃




¹³C NMR (101 MHz) of (*6S,7S,9R*)-**3j** in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3k in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-**3k** in CDCl₃





¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3l in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-3l in CDCl₃




¹H NMR (400 MHz) of (*6S,7S,9R*)-**3m** in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3n in CDCl₃




¹H NMR (400 MHz) of (*6R,7S,9R*)-**3n** in CDCl₃




¹³C NMR (101 MHz) of (*6R,7S,9R*)-**3n** in CDCl₃




¹H NMR (400 MHz) of (*6S,7S,9R*)-**3o** in CDCl₃




¹³C NMR (101 MHz) of (*6S,7S,9R*)-**3o** in CDCl₃




¹H NMR (400 MHz) of (*6S,7S,9R*)-**3p** in CDCl₃




¹³C NMR (101 MHz) of (*6S,7S,9R*)-**3p** in CDCl₃




¹H NMR (400 MHz) of (*6S,7S,9R*)-**3q** in CDCl₃




¹³C NMR (101 MHz) of (*6S,7S,9R*)-**3q** in CDCl₃




^1H NMR (400 MHz) of (*6S,7S,9R*)-**3r** in CDCl_3




^{13}C NMR (101 MHz) of (*6S,7S,9R*)-**3r** in CDCl_3





^1H NMR (400 MHz) of (*6S,7S,9R*)-**3s** in CDCl_3




^{13}C NMR (101 MHz) of (*6S,7S,9R*)-**3s** in CDCl_3







¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-3t in CDCl₃




¹H NMR (400 MHz) of (6*R*,7*S*,9*S*)-3t in CDCl₃




¹³C NMR (101 MHz) of (6*R*,7*S*,9*S*)-3t in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*R*,9*R*)-3u in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*R*,9*R*)-3u in CDCl₃




¹H NMR (400 MHz) of (*6R,7R,9S*)-**3u** in CDCl₃




¹³C NMR (101 MHz) of (*6R,7R,9S*)-**3u** in CDCl₃




¹H NMR (400 MHz) of (*6S,7S,9R*)-**3v** in CDCl₃




¹³C NMR (101 MHz) of (*6S,7S,9R*)-**3v** in CDCl₃




¹H NMR (400 MHz) of (*6R,7S,9S*)-**3v** in CDCl₃




¹³C NMR (101 MHz) of (*6R,7S,9S*)-**3v** in CDCl₃




¹H NMR (400 MHz) of (*6S,7S,9R*)-**3w** in CDCl₃




¹³C NMR (101 MHz) of (*6S,7S,9R*)-**3w** in CDCl₃




¹H NMR (400 MHz) of (*6R,7S,9S*)-**3w** in CDCl₃




¹³C NMR (101 MHz) of (*6R,7S,9S*)-**3w** in CDCl₃




^1H NMR (400 MHz) of (*6S,7S,9R*)-**3x** in CDCl_3




^{13}C NMR (101 MHz) of (*6S,7S,9R*)-**3x** in CDCl_3




¹⁹F NMR (376 MHz) of (6*S*,7*S*,9*R*)-**3x** in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-**3y** in CDCl₃




^{13}C NMR (101 MHz) of (*6S,7S,9R*)-**3y** in CDCl_3




^{19}F NMR (376 MHz) of (*6S,7S,9R*)-**3y** in CDCl_3




¹H NMR (400 MHz) of (*6S,7S,9R*)-**3z** in CDCl₃




¹³C NMR (101 MHz) of (*6S,7S,9R*)-**3z** in CDCl₃




¹⁹F NMR (376 MHz) of (6*S*,7*S*,9*R*)-3z in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3A in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-**3A** in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3B in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-**3B** in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3C in CDCl₃




^{13}C NMR (101 MHz) of (*6S,7S,9R*)-**3C** in CDCl_3




^1H NMR (400 MHz) of (*6S,7S,9R*)-**3D** in CDCl_3




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-**3D** in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3E in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-3E in CDCl₃




¹³C NMR (101 MHz) of (6*S*,7*S*,9*R*)-3F in CDCl₃




¹H NMR (400 MHz) of (6*S*,7*S*,9*R*)-3G in CDCl₃




^{13}C NMR (101 MHz) of (*6S,7S,9R*)-**3G** in CDCl_3




^1H NMR (400 MHz) of (*6R,7S,9S*)-**4** in CDCl_3




¹³C NMR (101 MHz) of (6*R*,7*S*,9*S*)-4 in CDCl₃




¹H NMR (400 MHz) of (6*R*,7*S*,9*S*)-5 in CDCl₃




¹³C NMR (101 MHz) of (6*R*,7*S*,9*S*)-5 in CDCl₃





¹H NMR (400 MHz) of (6*R*,7*S*,9*S*)-6 in CDCl₃



^{13}C NMR (101 MHz) of (*6R,7S,9S*)-**6** in CDCl_3



HPLC chromatogram of compound (*rac*)-3a [(6*S*,7*S*,9*R*)-3a + (6*R*,7*R*,9*S*)-3a]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.661	BV	0.1559	851.66162	83.12485	50.0017
2	6.185	VB	0.1745	851.60272	74.30883	49.9983

Totals : 1703.26434 157.43368

HPLC chromatogram of compound (*6S,7S,9R*)-3a



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	6.244	BB	0.1728	2980.98779	263.30911	100.0000

Totals : 2980.98779 263.30911

HPLC chromatogram of compound (6*R*,7*R*,9*S*)-3a



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.638	BV R	0.1552	1176.58679	115.58137	100.0000

Totals : 1176.58679 115.58137

HPLC chromatogram of compound (*rac*)-3a [(*6R,7S,9S*)-3a + (*6S,7R,9R*)-3a]



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1, Sig=230,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.016	MM	0.1414	8139.00537	959.13647	49.2437
2	5.512	MM	0.1527	2828.01750	664.11281	50.7562

Totals : 1,65280e4 1,783,25543

HPLC chromatogram of compound (*6R,7S,9S*)-3a



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1, Sig=230,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.000	BV R	0.1324	1.12364e4	1305.22974	99.6927
2	5.487	VB E	0.1570	34.63268	3.23317	0.3073

Totals : 1.12710e4 1308.46291

HPLC chromatogram of compound (6*S*,7*R*,9*R*)-3a



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs



Signal 1: DAD1, Sig=230,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.008	BV	0.1321	73.13862	8.52303	0.2756
2	5.495	VB	0.1682	2.64668e4	2447.50879	99.7244

Totals : 2.65400e4 2456.03182

=====
*** End of Report ***

HPLC chromatogram of compound (*rac*)-3a [(6*S*,7*S*,9*S*)-3a + (6*R*,7*R*,9*R*)-3a]



=====
=====
Area Percent Report
=====
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs



Signal 1: DAD1, Sig=230,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.620	BV	0.1490	6832.64551	681.40723	50.0163
2	7.304	VB	0.1719	6828.19971	594.87445	49.9837

Totals : 1.36608e4 1276.28168

=====
=====
*** End of Report ***

HPLC chromatogram of compound (6S,7S,9S)-3a



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs



Signal 1: DAD1, Sig=230,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.574	BB	0.1508	1.51093e4	1508.81506	100.0000

Totals : 1.51093e4 1508.81506

=====
*** End of Report ***

HPLC chromatogram of compound (6*R*,7*R*,9*R*)-3a



=====
=====
Area Percent Report
=====
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs



Signal 1: DAD1, Sig=230,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	*
1	7.305	BB	0.1726	1.23791e4	1073.22412	100.0000

Totals : 1.23791e4 1073.22412

=====
=====
*** End of Report ***

HPLC chromatogram of compound (*rac*)-3a [(6*R*,7*S*,9*R*)-3a + (6*S*,7*R*,9*S*)-3a]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.914	BV	0.2262	4582.09277	310.17975	49.7308
2	8.898	VB	0.2492	4631.70898	285.21521	50.2692

Totals : 9213.80176 595.39496

HPLC chromatogram of compound (6*R*,7*S*,9*R*)-3a



=====
=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs



Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.651	BB	0.2013	29.84655	2.29325	0.2797
2	8.556	BV R	0.2360	1.06411e4	692.69025	99.7203

Totals : 1.06709e4 694.98350

=====
=====
*** End of Report ***

HPLC chromatogram of compound (6S,7R,9S)-3a



=====
=====
Area Percent Report
=====
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs



Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.899	VV R	0.2209	7844.21289	543.11774	100.0000

Totals : 7844.21289 543.11774

=====
=====
*** End of Report ***

HPLC chromatogram of compound (*rac*)-3b [(6*S*,7*S*,9*R*)-3b + (6*R*,7*R*,9*S*)-3b]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.020	MM	0.1817	628.84509	57.68770	51.1761
2	6.745	MM	0.2057	599.94086	48.60559	48.8239

Totals : 1228.78595 106.29329

HPLC chromatogram of compound (*6S,7S,9R*)-3b



=====
=====
Area Percent Report
=====
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs



Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.641	MF	0.2036	3543.45850	290.00925	100.0000

Totals : 3543.45850 290.00925

=====
=====
*** End of Report ***

HPLC chromatogram of compound (*rac*)-3c [(6*S*,7*S*,9*R*)-3c + (6*R*,7*R*,9*S*)-3c]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.185	VV R	0.1431	860.56982	91.63569	49.2944
2	5.626	VB	0.1562	885.20770	86.19644	50.7056

Totals : 1745.77753 177.83213

HPLC chromatogram of compound (6S,7S,9R)-3c



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	5.663	VV R	0.1572	1622.17908	156.64230	100.0000

Totals : 1622.17908 156.64230

HPLC chromatogram of compound (*rac*)-3d [(*6S,7S,9R*)-3d + (*6R,7R,9S*)-3d]



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.619	MF	0.1409	8416.55469	995.77808	47.5114
2	4.964	FM	0.1568	9298.24512	988.02466	52.4886

Totals : 1.77148e4 1983.80273

HPLC chromatogram of compound (6S,7S,9R)-3d



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.597	BV E	0.1264	133.61182	16.27563	0.5954
2	4.937	VV R	0.1615	2.23072e4	2181.15747	99.4046

Totals : 2.24408e4 2197.43310

HPLC chromatogram of compound (*rac*)-3e [(6*S*,7*S*,9*R*)-3e + (6*R*,7*R*,9*S*)-3e]



=====
=====
=====
=====
=====
Area Percent Report
=====
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	4.711	VV R	0.1332	7163.95410	826.07642	50.6553
2	5.192	VB	0.1428	6978.61475	744.65002	49.3447

Totals : 1.41426e4 1570.72644

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3e



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.682	VV E	0.1444	147.38219	15.10049	1.2086
2	5.155	VV R	0.1445	1.20471e4	1275.94910	98.7914

Totals : 1.21945e4 1291.04959

HPLC chromatogram of compound (*rac*)-3f [(6*S*,7*S*,9*R*)-3f + (6*R*,7*R*,9*S*)-3f]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.268	VB R	0.1471	4571.70117	473.17191	49.2114
2	5.879	BB	0.1641	4718.22266	436.12241	50.7886

Totals : 9289.92383 909.29431

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3f



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.095	BV R	0.1772	1.90697e4	1666.02026	100.0000

Totals : 1.90697e4 1666.02026

HPLC chromatogram of compound (*rac*)-3g [(6*S*,7*S*,9*R*)-3g + (6*R*,7*R*,9*S*)-3g]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.624	BB	0.1615	1241.98657	117.14567	50.2863
2	6.569	BV	0.1902	1227.84534	98.76231	49.7137

Totals : 2469.83191 215.90798

HPLC chromatogram of compound (6S,7S,9R)-3g



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.566	MM	0.2026	43.29018	3.56189	1.6553
2	6.546	BV	0.1891	2571.99097	208.43007	98.3447

Totals : 2615.28115 211.99196

HPLC chromatogram of compound (*rac*)-3h [(6*S*,7*S*,9*R*)-3h + (6*R*,7*R*,9*S*)-3h]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.951	VV R	0.1824	1577.71741	128.63957	48.7474
2	9.291	BV R	0.2781	1658.79736	91.02004	51.2526

Totals : 3236.51477 219.65961

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3h



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs



Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.738	BB	0.2860	3391.60840	180.65225	100.0000

Totals : 3391.60840 180.65225

=====
*** End of Report ***

HPLC chromatogram of compound (*rac*)-3i [(*6S,7S,9R*)-3i + (*6R,7R,9S*)-3i]



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs



Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.198	VB	0.2425	9419.24414	582.71033	49.4766
2	9.777	BB	0.2771	9618.53418	523.12152	50.5234

Totals : 1.90378e4 1105.83185

*** End of Report ***

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3i



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	7.997	VB	0.2409	6045.53955	379.98526	100.0000

Totals : 6045.53955 379.98526

HPLC chromatogram of compound (*rac*)-3j [(6*S*,7*S*,9*R*)-3j + (6*R*,7*R*,9*S*)-3j]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.875	MM	0.2043	3241.12695	264.36353	49.6179
2	6.670	MF	0.2224	3291.05005	246.64017	50.3821

Totals : 6532.17700 511.00369

HPLC chromatogram of compound (*6S,7S,9R*)-3j



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.062	FM	0.1965	4065.51904	344.76599	100.0000

Totals : 4065.51904 344.76599

HPLC chromatogram of compound (*rac*)-3k [(*6S,7S,9R*)-3k + (*6R,7R,9S*)-3k]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.246	MF	0.1343	3769.24243	467.69119	49.9879
2	5.370	BV R	0.1521	3771.07007	370.63354	50.0121

Totals : 7540.31250 838.32474

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3k



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.337	MF	0.1644	5225.61182	529.67822	100.0000

Totals : 5225.61182 529.67822

HPLC chromatogram of compound (*rac*)-3I [(6*S*,7*S*,9*R*)-3I + (6*R*,7*R*,9*S*)-3I]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.055	MM	0.1549	1252.05444	134.75844	50.8594
2	6.009	BB	0.1676	1209.74036	110.03841	49.1406

Totals : 2461.79480 244.79685

HPLC chromatogram of compound (6S,7S,9R)-3l



=====
=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.029	BB	0.1685	5890.53418	531.89130	100.0000

Totals : 5890.53418 531.89130

HPLC chromatogram of compound (*rac*)-3m [(*6S,7S,9R*)-3m + (*6R,7R,9S*)-3m]



=====

Area Percent Report

=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.009	BB	0.1477	620.11047	64.15859	50.2034
2	5.779	BV R	0.1664	615.08685	55.84666	49.7966

Totals : 1235.19733 120.00525

HPLC chromatogram of compound (6S,7S,9R)-3m



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.017	VB R	0.1439	1752.58997	185.26711	100.0000

Totals : 1752.58997 185.26711

HPLC chromatogram of compound (*rac*)-3n [(6*S*,7*S*,9*S*)-3n + (6*R*,7*R*,9*R*)-3n]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.647	BB	0.1830	1683.97693	139.59908	50.6914
2	7.805	BB	0.2292	1638.04297	108.97227	49.3086

Totals : 3322.01990 248.57135

HPLC chromatogram of compound (6S,7S,9S)-3n



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.380	VB	0.1779	6436.46240	559.68188	100.0000

Totals : 6436.46240 559.68188

HPLC chromatogram of compound (6*R*,7*R*,9*R*)-3n



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.649	BB	0.1838	2214.52295	182.50430	100.0000

Totals : 2214.52295 182.50430

HPLC chromatogram of compound (*rac*)-3n [(6*R*,7*S*,9*R*)-3n + (6*S*,7*R*,9*S*)-3n]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=282 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.016	BV	0.2020	2656.27197	203.26733	50.8831
2	17.967	VV R	0.5646	2564.07178	68.76900	49.1169

Totals : 5220.34375 272.03633

HPLC chromatogram of compound (6*R*,7*S*,9*R*)-3n



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=282 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	18.830	VV R	0.6116	9057.90527	221.89972	100.0000

Totals : 9057.90527 221.89972

HPLC chromatogram of compound (6S,7R,9S)-3n



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=282 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.989	BB	0.1996	5855.35010	450.72839	100.0000

Totals : 5855.35010 450.72839

HPLC chromatogram of compound (*rac*)-3o [(6*S*,7*S*,9*S*)-3o + (6*R*,7*R*,9*R*)-3o]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=282,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.621	BB	0.3836	2941.39404	117.68037	50.2827
2	13.822	BB	0.5707	2908.32202	78.77827	49.7173

Totals : 5849.71606 196.45865

HPLC chromatogram of compound (6S,7S,9S)-3o



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=282,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.566	BB	0.3954	4885.49365	191.63930	100.0000

Totals : 4885.49365 191.63930

HPLC chromatogram of compound (*rac*)-3p [(*6S,7S,9R*)-3p + (*6R,7R,9S*)-3p]



=====
=====
=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.387	MF	0.1636	5233.17432	532.99854	50.8655
2	6.181	FM	0.1900	5055.08105	443.37534	49.1345

Totals : 1.02883e4 976.37387

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3p



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.177	MF	0.1899	7144.43945	627.18958	100.0000

Totals : 7144.43945 627.18958

HPLC chromatogram of compound (*rac*)-3q [(*6S,7S,9R*)-3q + (*6R,7R,9S*)-3q]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.194	BB	0.2588	3206.79517	187.93295	50.0065
2	11.264	BV R	0.3254	3205.96338	150.66389	49.9935

Totals : 6412.75854 338.59685

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3q



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.447	VV R	0.2616	5400.13086	314.33347	100.0000

Totals : 5400.13086 314.33347

HPLC chromatogram of compound (*rac*)-3r [(*6S,7S,9R*)-3r + (*6R,7R,9S*)-3r]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1, Sig=230,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.401	BB	0.1914	1238.24109	100.71017	49.7037
2	7.373	BB	0.2539	1253.00439	75.40665	50.2963

Totals : 2491.24548 176.11681

HPLC chromatogram of compound (6S,7S,9R)-3r



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1, Sig=230,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.173	BB	0.2467	4804.78516	297.09149	100.0000

Totals : 4804.78516 297.09149

HPLC chromatogram of compound (*rac*)-3s [(6*S*,7*S*,9*R*)-3s + (6*R*,7*R*,9*S*)-3s]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 B, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.238	VV R	0.2251	2248.14502	151.63770	49.0974
2	6.890	VB	0.2570	2330.80713	138.73984	50.9026

Totals : 4578.95215 290.37753

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3s



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1, Sig=230,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.895	BB	0.2549	3985.82813	239.86305	100.0000

Totals : 3985.82813 239.86305

HPLC chromatogram of compound (*rac*)-3t [(6*S*,7*S*,9*R*)-3t + (6*R*,7*R*,9*S*)-3t]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.990	BV R	0.1779	4311.48926	370.79184	49.4068
2	8.532	VV R	0.2686	4415.01416	251.88193	50.5932

Totals : 8726.50342 622.67377

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3t



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.504	FM	0.2964	1.82418e4	1025.91406	100.0000

Totals : 1.82418e4 1025.91406

HPLC chromatogram of compound (6*R*,7*R*,9*S*)-3t



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	5.965	BB	0.1773	9275.46875	801.03607	100.0000

Totals : 9275.46875 801.03607

HPLC chromatogram of compound (*rac*)-3t [(6*R*,7*S*,9*S*)-3t + (6*S*,7*R*,9*R*)-3t]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.550	MF	0.2089	2148.87085	171.40378	50.6454
2	8.681	MF	0.2398	2094.10596	145.52927	49.3546

Totals : 4242.97681 316.93304

HPLC chromatogram of compound (6*R*,7*S*,9*S*)-3t



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.780	VV R	0.1968	3523.16943	271.00604	100.0000

Totals : 3523.16943 271.00604

HPLC chromatogram of compound (6S,7R,9R)-3t



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	9.046	BB	0.2299	4604.00391	305.11819	100.0000

Totals : 4604.00391 305.11819

HPLC chromatogram of compound (*rac*)-3u [(6*S*,7*R*,9*R*)-3u + (6*R*,7*S*,9*S*)-3u]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.379	FM	0.1945	2709.29346	232.11978	50.2130
2	6.646	BV	0.2283	2686.31079	179.72554	49.7870

Totals : 5395.60425 411.84532

HPLC chromatogram of compound (6*S*,7*R*,9*R*)-3u



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A. Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.459	FM	0.3019	1.1928e-4	984.55157	100.0000

Totals : 1.19283e4 984 55153

HPLC chromatogram of compound (6*R*,7*S*,9*S*)-3u



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.736	BV	0.2310	2906.13525	192.97833	100.0000

Totals : 2906.13525 192.97833

HPLC chromatogram of compound (*rac*)-3u [(*6R,7R,9S*)-3u + (*6S,7S,9R*)-3u]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.013	BB	0.1326	1990.22046	230.88676	50.2550
2	10.640	BB	0.5021	1970.02393	60.28826	49.7450

Totals : 3960.24438 291.17502

HPLC chromatogram of compound (6*R*,7*R*,9*S*)-3u



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.045	BV R	0.5389	8926.01563	256.23291	100.0000

Totals : 8926.01563 256.23291

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3u



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	4.097	VV R	0.1364	4349.53662	493.10995	100.0000

Totals : 4349.53662 493.10995

HPLC chromatogram of compound (*rac*)-3v [(6*S*,7*S*,9*R*)-3v + (6*S*,7*S*,9*R*)-3v]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.040	BV R	0.2354	2016.88623	130.64432	49.3566
2	9.561	BV R	0.2903	2069.46729	108.81210	50.6434

Totals : 4086.35352 239.45641

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3v



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.520	VB R	0.2847	2842.49683	152.31169	100.0000

Totals : 2842.49683 152.31169

HPLC chromatogram of compound (*6R,7R,9S*)-3v



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.047	VV R	0.2471	7303.34668	451.09256	100.0000

Totals : 7303.34668 451.09256

HPLC chromatogram of compound (*rac*)-3v [(6*R*,7*S*,9*S*)-3v + (6*S*,7*R*,9*R*)-3v]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.530	MF	0.2982	1600.94043	89.48106	50.7714
2	10.343	BB	0.3530	1552.29163	68.18536	49.2286

Totals : 3153.23206 157.66641

HPLC chromatogram of compound (*6R,7S,9S*)-3v



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.628	MF	0.3011	1852.50439	102.54133	100.0000

Totals : 1852.50439 102.54133

HPLC chromatogram of compound (6*S*,7*R*,9*R*)-3v



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.595	BV R	0.2541	32.58307	1.74613	1.5923
2	10.400	BV R	0.3459	2013.67163	88.85639	98.4077

Totals : 2046.25470 90.60252

HPLC chromatogram of compound (*rac*)-3w [(*6S,7S,9R*)-3w + (*6R,7R,9S*)-3w]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.901	BB	0.4645	7769.15869	261.50870	49.6805
2	14.906	BV R	0.5193	7869.07617	232.98563	50.3195

Totals : 1.56382e4 494.49432

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3w



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.196	VB R	0.5359	6.88391e4	2039.37207	100.0000

Totals : 6.88391e4 2039.37207

HPLC chromatogram of compound (6*R*,7*R*,9*S*)-3w



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.844	BB	0.5226	4607.84668	135.29094	100.0000

Totals : 4607.84668 135.29094

HPLC chromatogram of compound (*rac*)-3w [(*6R,7S,9S*)-3w + (*6S,7R,9R*)-3w]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.875	MM	0.2043	3241.12695	264.36353	49.6179
2	6.670	MF	0.2224	3291.05005	246.64017	50.3821

Totals : 6532.17700 511.00369

HPLC chromatogram of compound (6*R*,7*S*,9*S*)-3w



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.960	MF	0.2202	2747.03101	207.89195	100.0000

Totals : 2747.03101 207.89195

HPLC chromatogram of compound (6S,7R,9R)-3w



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	6.062	FM	0.1965	4065.51904	344.76599	100.0000

Totals : 4065.51904 344.76599

HPLC chromatogram of compound (*rac*)-3x [(6*S*,7*S*,9*R*)-3x + (6*R*,7*R*,9*S*)-3x]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.001	BV R	0.1705	1142.04541	101.54745	49.7489
2	8.000	BB	0.2351	1153.57483	74.26209	50.2511

Totals : 2295.62024 175.80955

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3x



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.075	BB	0.2371	2261.91650	145.21368	100.0000

Totals : 2261.91650 145.21368

HPLC chromatogram of compound (*rac*)-3y [(6*S*,7*S*,9*R*)-3y + (6*R*,7*R*,9*S*)-3y]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.932	MM	0.1968	2658.22119	225.09253	51.9528
2	8.565	MM	0.2370	2458.38574	172.90269	48.0472

Totals : 5116.60693 397.99522

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3y



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.099	FM	0.1936	1547.30591	133.21687	100.0000

Totals : 1547.30591 133.21687

HPLC chromatogram of compound (*rac*)-3z [(6*S*,7*S*,9*R*)-3z + (6*R*,7*R*,9*S*)-3z]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.052	BV	0.1416	2296.94092	247.93579	50.0599
2	5.465	VB	0.1553	2291.44458	224.77055	49.9401

Totals : 4588.38550 472.70634

HPLC chromatogram of compound (6S,7S,9R)-3z



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	5.517	FM	0.1713	3101.19312	301.78656	100.0000

Totals : 3101.19312 301.78656

HPLC chromatogram of compound (*rac*)-3A [(6*S*,7*S*,9*R*)-3A + (6*R*,7*R*,9*S*)-3A]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=282 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.209	FM	0.2337	2124.41748	151.48035	50.0996
2	7.397	BB	0.2491	2115.97437	129.36566	49.9004

Totals : 4240.39185 280.84601

HPLC chromatogram of compound (6S,7S,9R)-3A



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=282 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.426	VV R	0.2518	5845.20459	355.07141	100.0000

Totals : 5845.20459 355.07141

HPLC chromatogram of compound (*rac*)-3B [(6*S*,7*S*,9*R*)-3B + (6*R*,7*R*,9*S*)-3B]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 B, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.930	BB	0.4275	7867.33057	294.70032	50.1456
2	10.552	BB	0.7660	7821.65430	156.24738	49.8544

Totals : 1.56890e4 450.94769

HPLC chromatogram of compound (6S,7S,9R)-3B



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1, Sig=260,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	10.579	BB	0.7489	1.95010e4	399.89008	100.0000

Totals : 1.95010e4 399.89008

HPLC chromatogram of compound (*rac*)-3C [(*6S,7S,9R*)-3C + (*6R,7R,9S*)-3C]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=280 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.075	VV R	0.2523	1498.13367	90.04637	50.0669
2	10.424	VV R	0.3431	1494.12988	65.91650	49.9331

Totals : 2992.26355 155.96287

HPLC chromatogram of compound (6S,7S,9R)-3C



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=280 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.879	VB R	0.2531	6262.44287	374.99780	100.0000

Totals : 6262.44287 374.99780

HPLC chromatogram of compound (*rac*)-3D [(*6S,7S,9R*)-3D + (*6R,7R,9S*)-3D]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=280 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.104	VV R	0.2869	2514.18677	132.51926	50.2497
2	10.735	MF	0.3983	2489.20459	104.16281	49.7503

Totals : 5003.39136 236.68207

HPLC chromatogram of compound (6S,7S,9R)-3D



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=280 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.151	MF	0.3135	1.07705e4	572.66125	100.0000

Totals : 1.07705e4 572.66125

HPLC chromatogram of compound (*rac*)-3E [((6*S*,7*S*,9*R*)-3E + (6*R*,7*R*,9*S*)-3E]



=====

Area Percent Report

=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.136	MM	0.1908	1238.59473	108.19269	51.3773
2	6.602	MM	0.2147	1172.18835	91.00120	48.6227

Totals : 2410.78308 199.19389

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3E



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.925	MF	0.1810	9434.40723	868.95294	100.0000

Totals : 9434.40723 868.95294

HPLC chromatogram of compound (*rac*)-3F [(6*S*,7*S*,9*R*)-3F + (6*R*,7*R*,9*S*)-3F]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.652	VB	0.1828	3079.36255	252.90845	50.2627
2	8.316	VB	0.2359	3047.17554	195.32420	49.7373

Totals : 6126.53809 448.23265

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3F



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.661	VR	0.1855	2264.36475	184.39798	100.00000

Totals : 2264.36475 184.39798

HPLC chromatogram of compound (*rac*)-3G [(*6S,7S,9R*)-3G + (*6R,7R,9S*)-3G]



=====
=====
Area Percent Report
=====
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.901	BB	0.4645	7769.15869	261.50870	49.6805
2	14.906	BV R	0.5193	7869.07617	232.98563	50.3195

Totals : 1.56382e4 494.49432

HPLC chromatogram of compound (6*S*,7*S*,9*R*)-3G



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.196	VB R	0.5359	6.88391e4	2039.37207	100.0000

Totals : 6.88391e4 2039.37207

HPLC chromatogram of compound (*rac*)-4 [(*6R,7S,9S*)-4 + (*6S,7R,9R*)-4]



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=230, 4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.222	MF	0.1856	7722.01611	693.60529	51.9452
2	6.874	FM	0.1955	7143.67578	609.05365	48.0548

Totals : 1.48657e4 1302.65894

HPLC chromatogram of compound (*6R,7S,9S*)-4



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=230,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.090	FM	0.1798	2.59645e4	2407.43652	100.0000

Totals : 2.59645e4 2407.43652

HPLC chromatogram of compound (*rac*)-5 [(6*R*,7*S*,9*S*)-5 + (6*S*,7*R*,9*R*)-5]



=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.261	VB R	0.1757	2168.16724	189.53319	50.5272
2	6.092	BB	0.1991	2122.91846	164.01160	49.4728

Totals : 4291.08569 353.54478

HPLC chromatogram of compound (6*R*,7*S*,9*S*)-5



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.038	BB	0.1983	2766.15430	214.80917	100.0000

Totals : 2766.15430 214.80917

HPLC chromatogram of compound (*rac*)-6 [(6*R*,7*S*,9*S*)-6 + (6*S*,7*R*,9*R*)-6]



=====

=====
Area Percent Report
=====



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.303	MM	0.1969	1.45133e4	1228.28394	48.2224
2	6.356	MM	0.2214	1.55832e4	1172.85889	51.7776

Totals : 3.00965e4 2401.14282

HPLC chromatogram of compound (6R,7S,9S)-6



=====
=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=230 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.278	MF	0.2079	2.27130e4	1821.03748	99.8595
2	6.305	FM	0.1942	31.95740	2.74292	0.1405

Totals : 2.27450e4 1823.78040